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ABSTRACT

Integrated Affinity Column/Capillary Electrophoresis
Microdevices for Biomarker Analysis

Weichun Yang
Department of Chemistry and Biochemistry
Doctor of Philosophy

In this dissertation, microfluidic systems that integrate antibody-based sample preparation
methods with electrophoretic separation are developed to analyze multiple biomarkers in
a point-of-care setting. To form an affinity column, both monolith materials and wallcoated channels were explored.
I successfully demonstrated that monolith columns can be prepared in microfluidic
devices via photopolymerization. The selectivity of monolith columns was improved by
immobilizing antibodies on the surface. These affinity columns can selectively enrich
target analytes and reduce the signal of contaminant proteins up to 25,000 fold after
immunoaffinity extraction. These results clearly demonstrate that microchip affinity
monoliths can selectively concentrate and purify target analytes through specific
antibody-antigen interactions.
These monolith columns operated well for simple systems such as buffered solution, but
suffered from clogging with real biological samples such as human serum. Therefore, I
developed new affinity columns using a wall coating protocol. To form the affinity
columns, a thin film of a reactive polymer was UV polymerized in a microchannel.
Antibodies were attached by reaction between the polymer epoxy groups and antibody
amine groups. All steps, including loading, washing, and elution for affinity extraction, as
well as capillary electrophoresis analysis, were achieved simply via applying voltages to
reservoirs on the microdevice. By adding reservoirs containing alpha-fetoprotein (AFP)
standard into the same device, a quantitative method, either standard addition or
calibration curve, can also be performed on-chip. These polymer microdevices have been
applied in determining AFP levels in spiked serum samples, and the results are
comparable with the values measured using a commercial enzyme linked immunosorbent
assay kit.
These microchips have also been adapted for detection of multiple biomarkers by
immobilizing different antibodies on the affinity column. Four kinds of antibodies were

attached to microchip columns, and the amounts of immobilized antibodies were
characterized. The fluorescence signals of all four protein antigens were in the same
range after rinsing, indicating that the derivatization reaction had little bias toward any of
the four antibodies. With spiked human blood serum samples, four proteins in the ng/mL
range were simultaneously quantified using both calibration curves and standard addition.
In general, the calibration curve and standard addition results were close to the known
spiked concentrations. These results indicate that my integrated microdevices can
selectively retain and analyze targeted compounds in clinical samples. Moreover, my
platform is generalizable and applicable for the simultaneous quantification of multiple
biomarkers in complex matrices.

Keywords: microfluidic systems, biomarkers, capillary electrophoresis, affinity extraction
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1. INTRODUCTION *

1.1 CANCER BIOMARKERS
1.1.1 Facts about cancer screening
Cancer (malignant neoplasms) is a group of many diseases where cells are abnormal
and divide without control. These tumor cells also can invade neighboring tissues and
spread to the whole body.1 Overall, cancer was not only the second most common
cause of death in the US (~23% of all deaths in 2006),2 but also has significant
financial impact. The National Institutes of Health (NIH) estimated that direct and
indirect costs associated with cancer were about $157 billion in 2001.3 More
importantly, many patients are diagnosed too late to be cured, as most cancer
treatments are more effective at early stages. For instance, the 5-year relative survival
rate for all patients with colorectal cancer is only 64%, but it can be improved to 90%
if tumors are detected at an early, localized stage.4 In one study, researchers found that
removal of polyps could reduce the incidence of colorectal cancer by 76 to 90
percent.5 Early cancer detection can also provide other significant advantages that
directly impact the quality of a person’s life. For breast cancer, many women have the
option of breast-conserving surgery rather than removal of the entire breast if
diagnosed early.6 Due to early stage diagnosis and other advances in cancer treatment,
cancer death rates began decreasing in the early 1990s. For instance, the death rate
from cancer decreased ~8.0% from 2001 to 2005 (Figure 1.1). Consequently, there
are tremendous opportunities to further improve the survival rate of patients by better
cancer screening and treatment methods.

*
Sections 1.2 to 1.3 in this chapter are adapted with permission from Journal of the Association for Laboratory
Automation, 2010, 15(3), 198-209. Copyright 2010 Elsevier
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Figure 1.1. Cancer death rates in the United States from 1975-2005. Source:
American Cancer Society. Cancer Statistics 2009 Presentation.
http://www.cancer.org/docroot/PRO/content/PRO_1_1_Cancer_Statistics_2009_pr
esentation.asp (Accessed date: 4/12/2010)
Currently, morphological examination of tumor biopsies is one of the most widely
used methods to diagnose cancer. However, this process is time-consuming,
uncomfortable and expensive. For instance, bone marrow biopsy requires an
anesthetic to numb the area, and a long needle is inserted into the marrow to aspirate
cells for study.7 Therefore, noninvasive screening tests such as ultrasound,
roentgenography, magnetic resonance imaging (MRI), computed tomography (CT),
and biomarker analysis are more attractive for early diagnosis and screening. Using
CT scanning, the internal structure of an object in a human body can be regenerated
from multiple X-ray projections. CT can detect minute angle differences in tissue, but
its contrast for soft-tissue is rather poor.8 Therefore, MRI, which has higher soft-tissue
contrast, is a commonly used alternative to CT. In addition, since MRI is based on the
distribution of hydrogen atoms, and unlike CT, MRI is safe for children and pregnant
women.6 Using imaging techniques such as CT and MRI for large-scale cancer
screening is still a continuing controversal topic due to non-reliable data and
inaccuracy.9, 10 Indeed, Beinfeld et al.11 calculated the cost-effectiveness of whole2

body CT screening, and concluded that on average a person will only get 6 more days
of life expectancy at a cost of $2500. Compared with CT and MRI, ultrasound is a
cheaper technique with comparable spatial and contrast resolution. However,
ultrasound images are collected manually and their quality is directly related to the
operator’s experience. Because the acoustic properties of bone and air are different
from soft tissues, bone and air bring shadows into ultrasound images. Thus, tissues
with bone and air interfaces such as lung tissue cannot be scanned well by
ultrasound.6

1.1.2 Biomarkers in cancer screening
On the other hand, biomarkers are a rapidly developing area in cancer research. There
are more than 160,000 articles with the “cancer biomarker” keyword in a Pubmed
database search. A cancer marker can be a molecule either produced by tumor cells,
or a specific chemical produced by the human body in response to tumor cells.12
These substances can be found in the blood, urine, and tissues. Different tumor
markers are found in different types of cancer, and levels of the same tumor marker
can be different depending on the type of cancer.13 The major benefits of using these
molecularly based biomarkers are the potential to: (1) assess the likelihood that cancer
will develop in high-risk groups, (2) diagnose cancer at an early stage, (3) evaluate
therapy treatment, and (4) guide new drug discovery.14

The validity of cancer biomarker tests is generally evaluated by two parameters:
sensitivity and specificity (Table 1.1).15 Sensitivity refers to the percentage of truepositive test results (A, individuals with cancer whose biomarker level is above T, the
action threshold) in all patients with cancer (M). Specificity refers to the percentage of
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true-negative results (D, individuals without cancer whose biomarker level is below T)
in all patients without cancer (N). Obviously, the values of both parameters are highly
dependent on the value set for T. If T is lower, A will be larger, which results in a
higher sensitivity number; however, D will be smaller which means it lowers the
specificity. Either way, an accurate determination of biomarker concentration will be
essential for biomarker discovery and application.

Table 1.1 Definition of sensitivity and specificity for biomarker screening tests.

Test result

With cancer

Without cancer

Above action threshold (> T,
positive)

True positive (A)

False positive (C)

Below action threshold (< T,
negative)

False negative (B)

True negative (D)

Total patients with cancer
(M=A+B)

Total individuals without cancer
(N=C+D)

Sensitivity=A/M × 100%

Specificity=D/N × 100%

To date, some markers such as prostate specific antigen (PSA) have been approved by
the US Food and Drug Administration for early detection of cancer.16 Another
example is thyro-calcitonin which has sufficient sensitivity and specificity for thyroid
cancer diagnosis.17 The American Society of Clinical Oncology (ASCO) first
published clinical practice guidelines for the use of tumor markers in breast and
colorectal cancer in 1996.18 In a recent update, the tumor markers considered (Table
1.2) were expanded from 7 to 13 categories.19 However, ASCO believes most of the
new markers (4 out of 6) are not sufficiently reliable and definitive for clinical usage.
In addition, some old markers such as p53 are still inadequately characterized for
application in disease management. Based on these guidelines, 6 categories of

4

Table 1.2 ASCO updated clinical practice guidelines for use of tumor markers in
breast cancer (adapted with permission from ref. 19).
Specific marker

Use

New markers since
the 2000 guideline

Change from the
2000 guideline

CA 15.3 and CA
27.29

monitoring patients with
metastatic disease during
active therapy
monitoring patients with
metastatic disease during
active therapy
predictive
factors
for
endocrine therapy

No

No

No

No

No

Yes

data are insufficient to
recommend
use
for
prognosis
prognosis, guiding use of
taxane chemotherapy, and
determining sensitivity to
endocrine therapy are not
recommended
data are insufficient to
recommend
use
for
management of patients
prognosis, evaluating risk of
recurrence
data are insufficient to
recommend
use
for
management of patients
data are insufficient to
recommend
use
for
management of patients
data are insufficient to
recommend
use
for
management of patients

No

No

No

Yes

No

No

Yes

Yes

No

No

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

CEA

ERs and PgRs
DNA flow cytometry

HER2

p53

uPA and PAI-1
Cathepsin D

Cyclin E

Proteomic analysis

Multiparameter gene
expression
Bone marrow
micrometastases
Circulating tumor cell
assays

predict the risk of recurrence
in patients treated with
tamoxifen
data are insufficient to
recommend
use
for
management of patients
application still under
investigation

Abbreviations: CA, carbohydrate antigen; CEA, carcinoembryonic antigen; ER, estrogen
receptor; PgR, progesterone receptor; HER, human epidermal growth factor receptor; uPA,
urokinase plasminogen activator; PAI-1, plasminogen activator inhibitor 1; CMF,
cyclophosphamide, methotrexate, and fluorouracil.
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biomarkers are recommended for clinical use, and only uPA and PAI-1 is
recommended for prognosis. Because the sensitivity and specificity of biomarkers are
highly dependent on the accurate measurement of biomarker levels in human fluids, a
fast, sensitive, and cost-effective method for biomarker analysis is highly desirable for
a clinical setting.

1.1.3 Current cancer biomarker analysis methods
Currently, most biomarkers are detected via immunoassays such as enzyme linked
immunosorbent assay (ELISA).20 This method was invented in the 1960s, and has
been heavily used in bioanalysis ever since.21 There are many different ways of
designing ELISAs, but in general, they involve at least one antigen-antibody pair and
an enzyme which generates a detectable signal.22 Table 1.3 and Figure 1.2
summarize commonly used ELISAs and their schemes. Immobilization of the antigen
of interest can be achieved by direct adsorption to the assay plate or indirectly via an
immobilized antibody. The antigen is then detected either indirectly (labeled
secondary antibody, Figure 1.2a) or directly (labeled primary antibody, Figure 1.2b,
c). A competitive ELISA is commonly used when the antigen is small and has only
one antibody binding site. Antigen from sample and the immobilized antigen compete
for binding to the labeled antibody. A decrease in signal indicates the presence of the
antigen in the sample (Figure 1.2d) when compared to assay wells with labeled
antibody alone (Figure 1.2e). One variation of this method is to use labeled antigen
instead of the antibody.23

Among these protocols, asymmetrical ELISA methodologies are widely applied in
commercial immunoassays since monoclonal antibodies are expensive. A commonly

6

(a)

(b)

(c)

(d)

(e)

Figure 1.2. Schematic diagram of commonly used ELISAs. (a) Antigen-coated
ELISA plate. (b) Symmetrical, and (c) asymmetrical two-site ELISA. Competitive
ELISA for antigen analysis using labeled antibody, (d) antigen is present in the
sample and (e) no antigen is in the sample.
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Table 1.3 Commonly used ELISAs.
Detected species
Antibody or

Antigen-coated
Non-competitive

Scheme
Figure 1.2a

antigen
Symmetrical

Antigen

Figure 1.2b

Asymmetrical

Antigen

Figure 1.2c

Labeled antibody

Antigen

Figure 1.2d, e

Labeled antibody

Antibody

Labeled antigen

Antigen

Labeled antigen

Antibody

Antibody-coated

Antigen-coated
Competitive
Antibody-coated

Table 1.4. Commercially available immunoassays for determination of alpha
fetoprotein (AFP) concentration.
Kit manufacturer

Panomics

Anogen

United

Pishtaz Teb

Biotech
Kit catalog #

BC1009

EL10049

CM-105

PT-AFP-96

ELISA format

Figure 1.2c

Figure 1.2b

Figure 1.2c

Figure 1.2c

Immobilized

Goat anti-AFP

Monoclonal

Monoclonal

Monoclonal

anti-human AFP

anti-AFP

anti-AFP

2.0-350

2.0-400

1.2-240

1.0-200

Monoclonal

Monoclonal

Anti-AFP-

Mouse monoclonal

anti-AFP-HRP

anti-AFP-HRP

HRP

anti-AFP-HRP

TMB

TMB

TMB

TMB

capture
Dynamic range
(ng/ml)
Conjugate

Substrate

Abbreviations: HRP: horseradish peroxidase; TMB, tetramethylbenzemidine.
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used combination is a monoclonal antibody as capture reagent and a polyclonal
antibody for detection. For alpha fetoprotein (AFP, a liver cancer biomarker) assays,
although the procedures and substrates are similar, different antibodies are used to
react with AFP in samples, resulting in different dynamic ranges and limits of
detection (Table 1.4). Consequently, it can be problematic to directly compare the
clinical data when different assays are used for quantifying biomarkers.24 In addition,
labor-intensive rinsing steps are involved in these assays (at least 5 washing steps),
and the total analysis time is about 2 hours. ELISA can simultaneously analyze ~100
samples in a clinical setting; however, this approach is more expensive (counting the
number of reference standards and reagents for each test) and less time effective for a
single or a few samples.

Thus, to develop a biomarker analysis system in a point-of-care (POC) setting,
analytical-grade diagnostic tools will need to be translated from conventional
laboratory facilities to “bedside” settings.25 As a consequence, many new biosensors
have been developed to offer low cost, high speed and high throughput. For example,

(a)

(b)

Figure 1.3. (a) Schematic of a typical MOSFET (D, drain; G, gate; ID, drain
current; S, source). (b) An example of nanowire biosensing. Introduction of antibiotin decreased the conductance of a biotin labeled NW, and NW conductance
returned to its original value after washing with buffer (reproduced with
permission from ref. 30).
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96-well plates can be transferred from the molded polymer to paper format.26 These
paper microzone plates require small volumes of sample (~5 μL) and are costeffective (about 5 cents for each plate).27,

28

New detector systems such as

semiconducting nanowires (NWs) configured as field-effect transistors (FETs) have
also been applied to detect proteins or cells in solution.29 The setup of these NWFETs is similar to conventional metal oxide semiconductor field effect transistors
(MOSFETs, Figure 1.3a): the NW serves as the wire connecting source and drain,
and the ions in the buffer solution serve as the gate. Once ions (such as biomarkers) in
bulk solution (such as serum) bind to the sensor surface, the gate potential changes
which in turn changes the channel current (Figure 1.3b).30 Such devices can also be
applied for T-cell detection by preparing deprotonated silanol groups on the NW. If a
T-cell is present in the solution, it brings extra H+ ions near the NW and increases
protonation of the NW surface, which decreases ID.31 These NW devices can directly
detect macromolecules without labeling, and the detection limit can be as low as 100
fM.32 However, the fabrication of these NWs is rather complicated, and significant
device-to-device variation was found even within the same batch.33 More importantly,
the Debye length (λD) is critical and must be carefully controlled in NW-FET devices.
A concentrated buffer solution (λD < 0.7 nm) effectively screens most of a protein’s
charge, resulting in baseline signal in a biotin-streptavidin system.34 Therefore, for
these surface-bound ligand NW systems, measurements must be performed in a low
salt (<1.5 mM) buffer solution. To overcome this shortcoming, Stern et al.35 recently
developed an ELISA to detect interleukin-2 in physiologically buffered solution.
Instead of using colorimetric methods as in traditional ELISA, changes in the local pH
value were used to monitor protein concentrations. However, a relatively complex
setup was needed for these nano-ELISA assays.
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Although these emerging technologies hold promise, an abnormal level of a single
biomarker alone is not generally sufficient to diagnose cancer.17 For example, many
men with PSA levels less than the 4.0 ng/mL action threshold had prostate cancer
detected by biopsy (i.e., false-negatives).36 Furthermore, PSA levels above 4 ng/mL
are associated with other conditions such as prostatitis, reducing the specificity (i.e.,
false-positives).37 To overcome these shortcomings, using a group of markers would
enable more sensitive and accurate cancer screening with higher throughput.38 There
are two common approaches to multiplex testing. One is series testing, where various
tests are performed one after the other. In general, the biomarker test is combined with
another methodology such as ultrasound, to improve sensitivity and specificity. The
other multiplex method is parallel testing, where all tests are performed at the same
time. Parallel testing is more commonly used in multi-biomarker analysis.

For

instance, Ward et al.39 found that the sensitivity of ovarian cancer diagnosis had
increased from 18% using CA125 alone to 64 % using human milk-fat globulin II as a
second marker and placental alkaline phosphatase as a third assay. Similarly, Yang et
al.40 evaluated 12 biomarkers for gastrointestinal cancer diagnosis, and a combination
of five markers significantly improved the diagnostic rate to ~40% relative to the
~27% rate achieved with just carcinoembryonic antigen (CEA). Thus, a biosensor
with readily accessible, portable, rapid, and multimarker assays would be ideal as a
POC platform.

1.2 MINIATURIZATION IN BIOCHEMICAL ANALYSIS
1.2.1 Advantages of microfabricated devices
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Since the early 1990s, there has been strong interest in the miniaturization of chemical
analysis systems,41 which provides new capabilities for chemistry, biology, and
medicine. These systems have the potential to influence broad areas, from biological
analysis to optics technology, because of their many advantages.42 For instance,
microfluidic devices offer low sample and reagent consumption (which is critical for
trace samples like biomarkers),43 small dead volume,44 high analysis speed (separation
in minutes or less),45 high throughput (up to 384 samples),46 and valveless flow
control (which enables integration of several functions).47 More importantly, for
diffusion-limited mixing processes like ELISAs, the diffusion time can be
significantly reduced in miniaturized devices, because the diffusion time decreases to
1/100th if the diffusion distance is 10-fold less.48 Consequently, a 2-hour assay in a
traditional 96-well plate (~1 cm diameter per well) could be accomplished in less than
1 second in a 100-μm microchannel. These advantages of microfabricated devices
have been exploited widely in biological analysis, and reviews cover areas such as
protein separation,49 cell analysis,50 genomics,51 and biomarker assays.25, 52

1.2.2 Microchip capillary electrophoresis
In 1981, Jorgenson et al.53 successfully transferred zone electrophoresis into the opentubular capillary format. A very high voltage can be applied in this technique, called
capillary electrophoresis (CE). The number of theoretical plates (N) in CE is only
proportional to the separation voltage (V, Eq. 1.1) if band broadening is limited to
diffusion:
N=

µ eV
2D
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(Eq. 1.1)

where μe is the electrophoretic mobility in the separation medium and D is the
diffusion coefficient of the analyte. With high voltages such as 30 kV, theoretical
plates near one million can be achieved.54

Once the voltage is applied to a buffer solution in a capillary or microchannel,
electrophoretic movement is not always the only driving force in the system. The
inner wall of the capillary acquires a charge in most cases. This is due to either
ionization of the wall (such as with fused silica) or adsorption of ions from the buffer
solution onto the wall (such as with Teflon). Both of these effects result in the
formation of a double layer of ions near the surface and a potential difference known
as the zeta potential.55 When a voltage is applied along this capillary, the outside of
the double layer (the mobile layer) is attracted to the electrode, and it drags the bulk
buffer solution with it. Such movement is called electroosmotic flow (EOF).56
Because EOF has a relatively flat profile compared with laminar flow, the molecules
move in narrow bands, giving a high separation efficiency in CE. When considering
EOF, μe in Eq. 1.1 should be replaced with the sum of electrophoretic and
electroosmotic mobility (μEOF):
( µ e + µ EOF )V
2D

N=

(Eq. 1.2)

And the migration time (tm) can be given by:
tm =

L2
( µ e + µ EOF ) × V

(Eq. 1.3)

where L is the separation length. The theoretical resolution of two components (A and
B) in CE can be given by:


V
Rs = 0.177( µ A − µ B ) 

 ( µ + µ EOF ) D 
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(Eq. 1.4)

where Rs is the resolution, μA and μB are the electrophoretic mobilities of the two
components, and µ is their average mobility. From Eq. 1.4, the best resolution will
be attained when µ +μEOF is very close to zero. The EOF can be changed via the
applied voltage, pH of the solution (changing zeta potential), temperature, organic
solvent addition, and surface modification.

From Eq. 1.3, with voltages of ~1 kV and separation lengths of ~1 cm, the migration
time can be a few seconds. Importantly, because N is independent of the column
length, miniaturized separation channels will not reduce separation efficiency,
provided the same overall voltage is applied. In contrast, shorter column lengths in
chromatography will result in a smaller number of theoretical plates, meaning reduced
separation efficiency. Consequently, microchip CE offers shorter analysis times
compared with traditional chromatography instruments. In addition, sample
processing such as preconcentration and purification can also be carried out in a single
device with potential automation. Moreover, because of the small dimensions of
microfabricated channels, Joule heat dissipation is more effective, and higher voltage
can be applied to improve separation efficiency. Thus, microchip CE has been widely
used in biological sample separation.41

1.2.3 Device materials
Initially, because of well-developed semiconductor technologies, many devices were
fabricated in silicon in the early stages of microfluidics. For instance, Terry et al.57
micromachined a gas chromatography (GC) system in a silicon wafer in the late
1970s. However, because silicon cannot withstand high potentials and it is very
difficult to use conventional optical detection methods with it, other materials have
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been explored in microfluidic applications. Due to its established fabrication methods
and characterized surface properties, glass was the dominant substrate material for
microdevices in the 1990s.58-60 However, the process of glass fabrication generally
involves HF etching and high bonding temperatures (>600˚C), which slow down the
whole process and are not desirable for mass production. On the other hand, polymers
offer a wide range of available materials to choose from based on desired properties.
For instance, polydimethylsiloxane (PDMS) is gas permeable (cells can grow inside a
device) and easy to bond to itself and glass (simple fabrication).61 Poly(cyclic olefin
copolymer) (COC) is chemically resistant to many organic solvents, which is suitable
for chromatography in microdevices.62 A review summarized commonly used
polymers in microfluidic systems, including their material properties, fabrication
methods, and device applications.63 In addition to the more common thermal
annealing technique (where the polymer interface is heated to near its glass transition
temperature causing the polymer chains to interdiffuse on the surface of the two
substrates), solvent can also be used to bond polymeric devices.64 The solvent
dissolves the surface of the polymeric material, and facilitates polymer chain
interdiffusion at the interface.65 In general, solvent bonding offers stronger enclosure
(withstands higher internal pressure than thermal bonding) and a fast bonding
process.64

1.2.4 Limitations of miniaturized devices
To date, many microfluidic designs have been made, but they are generally tested
with low complexity samples. For actual biological specimens, which are mixtures
with wide analyte concentration ranges, it remains a challenge to directly separate
even tens of compounds on microdevices. The small microchip platform size usually
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results in a short separation length, limiting the resolving power and peak capacity,
which are critical for separating complex mixtures.66 For a chromatographic or
electrophoretic system, the maximum number of separated elements (i.e., peak
capacity) can be calculated by:
n=L/w

(Eq.

1.5)
where L is the separation length and w is the mean value of the zone width.67 Because
separation lengths in microdevices are generally at the cm scale, the peak capacity is
rather low compared with conventional instruments. For instance, the peak capacity of
a PDMS microchip for micellar electrokinetic chromatography (MEKC) was only ~12
for protein separation.68 Importantly, to completely isolate a 20-component mixture
with 95% probability, the peak capacity should be ~800.69 Clearly, resolving power
and peak capacity in microfluidic systems could be improved. In addition, tiny sample
volumes (usually in the microliter range)70 are placed on microdevices, and often
nanoliter or smaller volumes are injected. Furthermore, microchips generally have a
short optical detection path,71 such that the detection limit is another aspect of
microfluidic devices that could be improved.

1.2.5 Integrating multiple functions in miniaturized devices
Fortunately, these separation and detection limitations can be overcome by integrating
multiple functions and components at the chip scale. Methods for microfluidic device
fabrication are generally based on photolithographic techniques, which make complex
designs possible.72 Moreover, fabrication techniques have been developed to transfer
these complex designs into low-cost materials like plastics.73, 74 By integrating sample
preparation processes into a single microdevice, trace samples can be preconcentrated
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before analysis. Multi-dimensional separations on-chip can significantly improve the
sample capacity. Importantly, because the samples in many integrated microdevices
are manipulated by voltages, these microfluidic systems can be readily automated.
Compared with traditional methods, automated sample analysis can be more
economical, requiring less human intervention, and enabling increased sample
throughput.75 Consequently, these advantages make integrated microdevices
especially attractive for automating the characterization of complex mixtures.

1.3 ON-CHIP SAMPLE PREPARATION
1.3.1 Dynamic preconcentration techniques
Sample concentration techniques in CE, such as sweeping and stacking, have been
proven effective for pharmaceutical species,76 herbicides,77 steroids,78 and peptides.79
The principle of stacking is based on the conductivity difference between sample and
buffer zone. Briefly, a sample solution with a low conductivity is introduced into a
capillary filled with buffer solution with a high conductivity. After applying a voltage
on the capillary, the local electric field in the sample zone is higher than the buffer
zone since the electric current in the capillary is constant. Therefore, the analytes in
the sample zone move faster than in the buffer zone, which results in concentrating
the analytes at the boundary. Generally, stacking can easily provide over l00-fold
enhancement of the ionic analytes.80 These methods have also been applied in
microfluidic formats. For instance, Jung et al.81 developed a porous-polymer plug in a
microchannel to create a high conductivity buffer zone and enriched fluorescent
analytes 1000-fold using field-amplified sample stacking. The same group developed
CE microchips coupled with isotachophoresis (ITP), which could enrich Alexa Fluor
488 nearly two million fold,82 and under optimized conditions the detection limit of
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Alexa Fluor 488 was ~100 aM.83 For ITP preconcentration, a sample is loaded
between a fast leading electrolyte and a slow terminating electrolyte. After applying a
voltage and reaching equilibrium, since the current through the entire column is the
same, the electric field is smaller for faster bands and larger for slower bands.
Consequently, each sample component is migrating in a band at the same
electrophoretic mobility. The boundary between bands is sharp and discrete.56
However, it is important but difficult to find suitable leading and terminating
electrolytes for ITP. A review on stacking and sweeping in microchip systems was
recently published.84 These traditional dynamic techniques have been easily
transferred from CE systems to microchip CE systems, while providing effective
enrichment. For instance, Bercovici et al.85 developed a method for identification of
unlabeled analytes using indirect fluorescence-based detection and ITP on
commercially available microfluidic borosilicate chips. Such systems can also be
applied for chemical toxin detection in tap water without sample preparation steps.86

One interesting area within dynamic preconcentration techniques is equilibrium
gradient focusing, including electric field gradient focusing (EFGF) and temperature
gradient focusing.84 Equilibrium gradient focusing is attractive for isolating and
concentrating trace proteins. In EFGF, an equilibrium band is formed for each protein
when the electrophoretic velocity is equal in magnitude, but opposite in direction to
the hydrodynamic counterflow. EFGF was developed by Koegler and Ivory87 using a
tapered glass cylinder to generate the electric field gradient. Humble et al.88
successfully transferred EFGF into capillary format, and 10,000-fold preconcentration
was achieved for green fluorescent protein (GFP). Kelly et al.89 used a phasechanging sacrificial layer to protect a microchannel during formation of a designed
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conductive polymer which generated an electric field gradient in a microdevice. Liu et
al.90 applied a different approach to divide the separation channel from the electric
field generating component. A buffer ion-permeable membrane was integrated into
the microdevice to divide the separation and field channels, and GFP was
concentrated up to 4,000-fold using this device. To reduce non-specific adsorption,
EFGF devices can be completely fabricated from a poly(ethylene glycol) based
polymer,91 and the performance can be further improved by replacing the Tris buffer
in the hydrogel with KCl-phosphate buffer.92

1.3.2 Solid phase extraction
Solid phase extraction (SPE) is a widely used method for sample preparation. It can
be fully automated with commercial systems like SPE-DEX (Horizon Technology),
OSP2 (Merck), and MicroLab SPE (Hamilton).93 In SPE, sample is retained on a solid
medium, allowing the matrix to be rinsed away and the retained material to be eluted
for analysis.94 The promise of sample enrichment and cleanup by SPE has led
researchers to apply this approach in microdevices. A SPE column has been fabricated
by coating microchip walls with silanes, and 80-fold preconcentration of coumarin
C460 was observed;95 however, due to the limited surface area, the loading capacity
of this approach was relatively low.

1.3.2.1 Packed bead columns
Because silica beads are commercially available and their properties are well
characterized, microchip SPE columns made by packed beads are attractive. However,
it is necessary to localize these particles in targeted regions of microchips using
physical barriers. For example, a sol-gel structure was fabricated to retain silica beads,
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and this system was tested in on-chip DNA purification.96 In an alternate format, a
two-weir design which constructed a cavity to trap beads was explored.97 Two
photomasks were used in device fabrication, one to pattern the tops of the weirs for
etching, and the other to pattern the channels for etching to a different depth. In this
manner, a 1-μm gap was formed to prevent beads from passing out from the SPE
bed.98 Zhong et al.99 developed a two-side etching and alignment protocol to construct
weirs in a different manner. A top plate containing weirs and a bottom plate having
the connection channels were aligned, and a 4-μm gap was created by sealing the
plates together. Instead of a microfabricated weir structure, a physical barrier can be
prepared on-chip with a photopolymerized frit.100 In a different approach, beads can
be packed through a tapered geometry by the keystone effect.101 The channel which
contained the beads tapered from a 70-μm to a 16-μm width. When beads flowed
through the channel, the density of the particles increased in the taper, such that they
aggregated without a physical barrier.

1.3.2.2 Monolith columns
Packed-bead columns have disadvantages in terms of packing procedures and frit
fabrication, which complicate microdevice preparation. On the other hand, monoliths
are an attractive alternative to packed particles because of low back pressure and high
surface area.102 Thermally polymerized monolith materials have been successfully
applied as SPE columns.103 In 2001, Yu et al.104 photopolymerized a monolith column
in a microfluidic system and performed SPE. Enrichment of peptides and proteins up
to 1000 fold was achieved on this column. More importantly, due to low back
pressure, the linear flow rate in these monoliths could reach 10 μL/min, which far
exceeded flow in packed microchip columns.
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Monolith columns have also been applied for DNA enrichment in complex mixtures
like blood. However, nonspecific binding hindered elution of nucleic acids and
decreased sample loading capacity due to competitive adsorption; the presence of
proteins lowered the monolith extraction efficiency from ~80% to <40%.105 Therefore,
Wen et al.106 developed a two-stage microchip SPE system. Before monolith column
extraction, a C18 reversed-phase column was used to remove proteins in the sample.
Although the procedure was more complex, whole blood DNA extraction capabilities
were significantly improved. For a 10-μL whole blood sample, ~70% of the protein
was removed by the C18 column, which then afforded more interaction between DNA
and the monolithic material. This two-stage system enriched DNA ~20 fold in the
reversed-phase portion, and the overall DNA extraction efficiency was ~70%.

1.3.2.3 Affinity columns
In the previous applications, SPE enriched analytes based on general interactions like
hydrophobic absorption. To improve the selectivity, affinity elements can be
immobilized on the column. In general, the immobilization of an antibody to a solid
support is obtained via one of four main functional groups of the antibody molecule
(Figure 1.4):107 ε-amino groups of lysine,108 carbohydrate residues in the Fc region of
the antibody,109 carboxyl residues110 and sulfhydryl groups111 of the reduced
antibodies. The formation of a covalent bond between the antibody and the column
can enhance the stability compared with direct adsorption methods,112 which is critical
for flow-through systems or high pressure systems. In some cases, antibodies can also
be immobilized via another antibody, which is specific to the Fc portion of the first
antibody.113
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Antibody

immobilization

has

been applied successfully in a
microfluidic

format.

For

instance, rabbit immunoglobulin
G was concentrated and detected
at the 50 nM level.114 However,
this approach is only effective in
capturing

target

analytes

in

simple buffer solutions instead
of complex matrixes like tissue
or blood. Phillips and Wellner115,
Figure 1.4. Antibody structure. (adapted with
permission from ref. 107)
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have utilized immunoaffinity

CE to measure biomarkers and
neuropeptides in human biopsies. The analytes were captured by a replaceable
immunoaffinity disk having attached antibodies. After removing non-target materials,
the captured analyte was labeled in situ, released, and then separated by microchip CE.
The system was semi-automated, and the separation step was completed within 5 min.

Surface modification can be achieved on monolithic materials as well. For instance,
glycoproteins were retained on a monolith with immobilized pisum sativum
agglutinin, and then eluted in several fractions due to different affinities.117 Recently,
He et al.118 prepared a streptavidin acrylamide gel to immobilize biotinylated
antibodies. The blotting membrane effectively reduced antibody consumption to ~1
μg and could detect as little as 0.05 pg of protein. This approach has recently been
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extended into a 2-D system,119 where the entire process for immunoblotting, including
separation, sample transfer, and antibody-based blotting, was performed in less than 2
min.

Non-electrically driven immunoassays can also be performed in microchip devices.
For instance, Kong et al.120 formed elastomeric microvalves in 3-layer microchips to
control flow, although the valves were actuated by a vacuum pump and a compressor.
Using this system, clenbuterol was determined in pig urine samples in 30 min. Fan et
al.121 designed a PDMS-on-glass microsystem to perform protein assays on blood
samples. Plasma was separated from whole blood on chip, and selected proteins were
detected by antigen-antibody interaction. Stern et al.122 developed an affinity
extraction chamber coupled with a label-free nanosensor to detect PSA and CA15.3 in
human blood. In this study, a two-stage approach with a valve was applied to isolate
the detector from the complex environment of whole blood.

1.3.3 Membrane filtration
Another common method for sample preconcentration and cleanup is membrane
filtration, which utilizes the size difference between analytes and buffer ions. Larger
molecules cannot pass through a porous layer in a semipermeable hollow fiber,123
membrane,124 or joint,125 while smaller species are allowed to transit. In one design, a
porous membrane was sandwiched between two PDMS pieces to create a threedimensional microfluidic channel structure.126 This system achieved 300-fold
concentration of fluorescein in around 40 min. The fluorescein was concentrated
outside a 10-nm pore membrane with openings larger than the molecular size of
fluorescein, because the negatively charged diffuse layer on the interior of the
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membrane repelled anions. Song et al.127 used a laser to pattern a nanoporous
membrane at the junction of a cross channel. This device could concentrate proteins
over 100–fold in 2 min, and the degree of concentration was limited only by analyte
solubility. Similarly, an anionic polyacrylamide gel preconcentrator was laser
photopolymerized in one arm of a cross channel in a PMMA microdevice.128 The
negatively charged sulfonate groups in the gel repelled negatively charged proteins,
enabling concentrating of proteins up to 100,000-fold. Foote et al.124 used a silicate
membrane deposited between two adjacent microchannels, and a ~600-fold signal
increase for proteins was achieved. Kim and Han129 developed a simple protocol to
fabricate a nanoporous membrane in microdevices. They used razor blades to form a
gap in the microchannels in a PDMS substrate; Nafion 117 was then filled into the
gap and a portion of the microchannels via capillary forces. In this protocol,
preconcentration was achieved in large channels with dimensions up to 1 mm.

Semi-permeable membranes can also be integrated with other microchip
functionalities. Herr et al.130 fabricated a size-exclusion membrane at the injection
junction of a microdevice, allowing antibody enrichment at the membrane surface.
Sample loaded on the membrane was captured via antigen-antibody interaction, and
enriched species were eluted into a separation channel for electrophoretic
immunoassay. This system measured a biomarker for periodontal disease in saliva in
<10 min with comparable results to ELISA. A similar design has been developed into
a portable diagnostic format for rapid detection of biological toxins.131 A membrane
can also be used for SPE. Lion et al.132 integrated a poly(vinylidene difluoride)
membrane to desalt and concentrate samples before analyzing with mass spectrometry.
Kim and Gale133 sandwiched an aluminum oxide membrane between PDMS pieces;
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when a blood sample passed through the membrane, DNA was selectively enriched
and then eluted with buffer. The extraction time was <10 min while the recovery was
~40 ng of DNA per microliter of blood. A membrane has also been applied to enrich
nonvolatile analytes by evaporation to reduce the amount of liquid phase.134 The
membrane was located at the interface between a gas and liquid channel; sample was
introduced into the liquid channel, and water was evaporated into the gas channel
through which nitrogen flowed.

In addition to the size exclusion mechanism, ion concentration polarization135 can also
be used to enrich biological samples. By applying a DC voltage on a cation-selective
membrane, cations can enter the nanochannel under the voltage, while anions are
driven away from the nanochannel. Consequently, the local ion concentration on the
anodic side of the membrane decreases and forms an ion depletion zone. This
depletion thickens the Debye layer and causes it to overlap in a nanofluidic channel.
Electrical double layer overlap gives the nanochannels a preference for cation transfer
and speeds up the concentration polarization. Hence, an extended space charge layer
is formed near the membrane, and negatively charged analytes such as proteins can be
continuously trapped and collected. The process can be maintained for several hours,
resulting in million-fold enrichment.136 This technique can be used for affinity,137
enzyme,138 and cellular kinase activity assays.139 Because both antibody (or enzyme)
and antigen (or substrate) are trapped in a small region, the reaction time is
significantly shorter while sensitivity is improved. For instance, a kinase assay took
less than 10 min, and the sample volume was as low as 5 cells in the cellular assay.139
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1.4 DISSERTATION OVERVIEW

In my dissertation, I describe efforts to develop new approaches to quantify several
biomarkers in human serum using integrated microfluidic devices. Microfluidic
technologies have been applied extensively in rapid sample analysis. Some current
challenges for standard microfluidic systems are relatively high detection limits, and
reduced resolving power and peak capacity compared to conventional approaches.
The integration of multiple functions and components onto a single platform can
overcome these separation and detection limitations of microfluidics. I show that onchip sample preparation, including cleanup and preconcentration, can serve to speed
up and automate processes in integrated microfluidic systems. This chapter has
provided a brief overview of integrated multi-process microfluidic systems for
biological sample analysis. My work in the following chapters focuses on monolith
columns, affinity columns and membrane filtration described in Section 1.3.

In Chapter 2, I present the design, fabrication and evaluation of monolith materials for
off-chip solid phase extraction. Monoliths were prepared in microfabricated channels
in situ by UV photopolymerization. This chapter serves as a proof of concept for SPE
in microfluidic devices. These devices were used to enrich fluorescently labeled
amino acids 20-fold and purify them from a mixture containing a contaminant protein.
However, the off-chip extraction done in Chapter 2 slows the overall analysis speed
and efficiency. Therefore, affinity column extraction and microchip CE have been
integrated into one platform in Chapter 3. Sample loading, rinsing, elution, and
separation were performed in an automated manner on a single chip by controlling
potentials applied to appropriate reservoirs. FITC-tagged proteins were purified from

26

other contaminant species by an anti-FITC column and then separated by rapid
microchip CE.

All samples tested on monolith columns in Chapters 2 and 3 were in simple buffer
solutions, but for complex mixtures such as human serum, the monolith column can
be easily clogged. In addition, acidic buffer was used to interrupt the antigen-antibody
interaction and elute target components off the column, which significantly decreased
the fluorescence signal. To address these issues in Chapter 3 I integrated additional
functions, including online titration of acidic eluent and on-chip quantitation into
these microdevices. Furthermore, affinity columns were fabricated via a wall-coated
thin film of reactive polymer instead of monolith to alleviate column clogging with
real samples. These systems can quantify AFP at ~1 ng/mL levels in ~10 µL of
human serum in a few tens of minutes. AFP concentrations measured in these
microdevices using both calibration curve and standard addition methods compared
favorably with those determined using a commercial ELISA kit.

In Chapter 4, I demonstrate the quantitation of four cancer biomarkers in human
serum using my integrated microdevices. After coating a thin film of reactive polymer
in a microchannel, four antibodies were covalently immobilized to it. The retained
protein amounts were consistent from chip to chip, demonstrating reproducibility.
Furthermore, the signals from four fluorescently labeled proteins captured on-column
were in the same range after rinsing, indicating the column has little bias toward any
of the four antibodies or their antigens. These affinity columns have been integrated
with capillary electrophoresis separation, enabling simultaneous quantification of four
protein biomarkers in human blood serum in the low ng/mL range using either a

27

calibration curve or standard addition. These results could be easily adapted for
detection of other biomarkers by simply immobilizing different antibodies in the
affinity column. This system could also be expanded to detect ~30 biomarkers by
immobilizing additional different antibodies on the affinity column, in conjunction
with longer separation channels and spectral multiplexing to improve peak capacity.

Finally, in Chapter 5, I give general conclusions regarding my work and consider
future directions for the field.
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2. AFFINITY MONOLITH PRECONCENTRATORS FOR
POLYMER MICROCHIP CAPILLARY
ELECTROPHORESIS *

2.1 INTRODUCTION
Clinical assays, biological analysis, and pharmaceutical effectiveness studies
increasingly require the monitoring of multiple analytes in complex mixtures. For
instance, to detect cancer and other diseases at early stages, biomarker detection in
bodily fluids is used widely.1 However, these species often have low abundances and
are in complex matrices.2 Consequently, it is an ongoing challenge to detect trace
analytes in real samples.

Since the early 1990s, there has been strong interest in the miniaturization of chemical
analysis systems.3 Such instrumentation offers small volume analysis, fast separation,
and the potential to combine multiple processes in a single device. Despite successful
applications in areas such as biomarker assays,4 a major challenge with microfluidic
devices is the detection limit, because small sample volumes (in the microliter range)
can be loaded on chip,5 and the optical path for detection is short (typically <100
μm).6 In addition, the separation length in microdevices limits the resolving power,
which is critical for analyzing complex mixtures.7 As a consequence, sample
preconcentration and pretreatment will play an important role in the determination of
trace analytes in biological specimens using miniaturized devices.

*
This chapter is reproduced with permission from Electrophoresis, 2008, 29, 3429-3435. Copyright 2008 WileyVCH Verlag GmbH & Co.
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Traditional sample concentration techniques in capillary electrophoresis (CE)8 such as
sweeping and stacking have been shown for molecules like pharmaceutical species9
and peptides10. Moreover, the stacking technique has been integrated into
microdevices.11 However, in stacking, the conductivity of the sample matrix must be
lower than the running buffer,12, 13 constraining experimental conditions. Other online
concentration methods have also been reported that utilize the size difference between
analytes and buffer ions. These techniques take advantage of the inability of larger
molecules to pass through a porous layer in a semipermeable hollow fiber,14
membrane15 or joint,16 while smaller ions are allowed to transit. However, complex
device fabrication and detection instrumentation are needed for these systems.

Solid phase extraction (SPE) is a widely used method for sample preparation, in
which a targeted analyte is retained on a column to separate it from the matrix and is
then eluted for analysis.17 The promise of enriching samples by SPE has led
researchers to apply this approach in microdevices. In one study, microchip walls
were coated with silanes to form an SPE column, and 80-fold preconcentration was
observed;18 however, due to the limited surface area, the loading capacity of this
approach was relatively low. To address loading, silica bead19 and polymer
monolith20, 21 SPE columns have also been integrated into microdevices. Silica bead
columns have disadvantages in terms of packing and frit fabrication, which
complicate microdevice preparation. On the other hand, monoliths are an attractive
alternative to packed particles because of low back pressure and relative ease of
column formation.22
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However, SPE in as-formed monoliths typically has low selectivity. In addition,
nonspecific binding sites hinder elution of desired analytes and decrease sample
loading capacity due to competitive adsorption. One way to overcome these
shortcomings is to introduce a precolumn to remove most interferences from the
matrix. Landers’ group23 recently demonstrated a packed octadecyl bead precolumn
coupled with monolith extraction on chip, which increased the loading capacity
around 100-fold for DNA analysis. An alternative approach to improve selectivity is
to immobilize enzymes or antibodies on a monolith. In fact, solid-phase supports have
been used for the attachment of enzymes since the 1970s.24 A recent review
summarizes the application of monoliths as supports for attaching protease enzymes
in protein mapping.22 These studies indicate a promising future for monolithic
materials as pretreatment columns for biological samples.

Here I demonstrate a technique for in situ preparation of sample pretreatment
monoliths in microfluidic devices. These monoliths are integrated readily into
microdevices and used as SPE columns for sample preconcentration and pretreatment.
I demonstrate the preconcentration of amino acids on monoliths to show the general
nature of this approach. To enhance extraction selectivity, I immobilized antibodies
on monoliths and blocked nonspecific adsorption sites. I have used these affinity
monoliths to enrich fluorescently labeled amino acids 20-fold and purify them from a
mixture containing a contaminant protein. My results build a foundation for future
fabrication of fully integrated sample preparation and separation microdevices for
fast, sensitive, and inexpensive protein analysis.
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2.2 MATERIALS AND METHODS
2.2.1 Reagents and materials
All amino acids except Trp were obtained from ICN Biomedicals (Aurora, OH).
Lysozyme (95% protein), hydroxypropyl cellulose (HPC, average MW 100,000), Trp
(99%), glycidyl methacrylate (GMA, 97%), ethylene dimethacrylate (EDMA, 98%),
2,2-dimethoxy-2-phenylacetophenone (DMPA, 99%), and 1-dodecanol (98%) were
purchased from Sigma-Aldrich (Milwaukee, WI). PBS-EDTA coupling buffer (pH
7.2), sulfo-SMCC, and 2-mercaptoethylamine (MEA) were from Pierce (Rockford,
IL). FITC was from Molecular Probes (Eugene, OR). Ethylenediamine (EDA) and
Tris (electrophoresis grade) were from Fisher (Fair Lawn, NJ). Cyclohexanol (100%)
was from J.T. Baker (Phillipsburg, NJ). Anti-FITC was from Biomeda (Foster City,
CA). Green fluorescent protein (GFP, 1.0 mg/mL) was from BD Biosciences (San
Jose, CA). Sodium azide was from Merck (Darmstadt, Germany). All solutions were
prepared with deionized water (18.3 MΩ-cm) purified by a Barnstead EASYpure
UV/UF system (Dubuque, IA). Poly(methyl methacrylate) (PMMA, Acrylite FF, 3mm thick) was from Cyro Industries (Rockaway, NJ) and was cut to 1.8×5.0 cm2 by a
CO2 laser cutter (C200, Universal Laser Systems, Scottsdale, AZ) before use.

2.2.2 Device fabrication
Two kinds of microdevices were utilized in this study (Figure 2.1): extractor and
separation chips. The fabrication protocol was adapted from previous work in Dr.
Woolley’s lab to transfer the pattern from photomasks to polymeric devices.25 A ~0.5
μm thickness of silicon dioxide was grown on a 4-inch silicon <100> wafer by
flowing a humidified oxygen stream at 1110 °C for 90 min. The oxidized wafer was
then spin-coated with a thin film (~1 μm) of Shipley 812 photoresist, and prebaked on
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a hot plate at 110 °C for 60 s to remove residual solvent and improve adhesion of the
photoresist to the wafer. The photoresist was exposed to UV light for 10 s through a
patterned photomask fabricated on chrome-coated glass in the Integrated
Microfabrication Lab at Brigham Young University (BYU). After UV exposure, the
wafer was submerged in Shipley MF-26A developer for 30 s to remove the exposed
photoresist. The substrate was rinsed with water and postbaked in a preheated oven
for 15 min at 120 °C to remove any remaining water and promote the adhesion of the
remaining photoresist.26 After postbaking, the wafer was immersed in 10% buffered
HF for 7 min to remove the unprotected silicon dioxide. Finally, the pattern was wet
etched to a ~20 μm depth in 40% aqueous KOH solution for 20 min at 70 °C. The
etched silicon wafer served as a hot embossing template.

PMMA

substrates

were

imprinted by hot embossing

b
5

a

at 140 °C for 30 min using
2

4

3

etched Si templates. The
patterned PMMA was then
1

thermally bonded at 110 °C
6

for

30

min

unimprinted
Figure 2.1. Schematic diagram of microchips; (a) an
extractor chip and (b) a separation chip. In (a) the
0.5-cm-long monolith is formed between reservoirs
1 and 2. In (b) reservoir 3 is for sample and reservoir
4 is for injection waste. The separation channel
connects reservoirs 5 and 6. The distance from the
intersection to reservoirs 3-5 is 0.5 cm, and the
distance to reservoir 6 is 3.5 cm.

an

PMMA

substrate with drilled holes
for

reservoirs.

Channel

widths at half height were
50 µm, and channel depths
were 20 µm.
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Porous polymer monoliths (0.5-cm long) were prepared in the extraction microchip
(Figure 2.1a) by photoinitiated in situ polymerization. Monoliths were made from
GMA and EDMA monomers with DMPA as the photoinitiator. Cyclohexanol and 1dodecanol were used as the porogen. The monolith preparation followed published
procedures.27-29 Briefly, 0.005 g DMPA, 0.4 g GMA and 0.6 g EDMA were mixed in
a 4-mL glass vial. Porogen (0.3 g cyclohexanol and 0.7 g 1-dodecanol) was added
slowly to the mixture. Before polymerization, the solution was sonicated in a water
bath for 3 min followed by nitrogen purging for 3 min to remove dissolved oxygen.
The degassed mixture was aspirated into the microchannels by vacuum, and excess
monomer in the reservoir was removed by pipet to minimize siphoning during
polymerization.30 Next, the microchip was partially covered with electrical tape or
aluminum foil to provide spatial control over polymerization. The microchip was then
put on a cooled aluminum plate and exposed to UV light (200 mW/cm2) in the
wavelength range of 320–390 nm for 10 min. Cooling the device helped eliminate
undesired thermal polymerization.30 Finally, unreacted monomer and porogen were
removed by flushing 2-propanol through the microchannels using a syringe pump.

2.2.3 Tris-reacted monoliths
For general analyte preconcentration, the reactive GMA epoxy groups were blocked
using Tris buffer (100 mM, pH 8.4) pumped through the monolith and incubated for
24 h at room temperature.31 This protocol is based on the chemical reaction between
GMA epoxy groups and Tris amine groups. The monolith was then rinsed with water
using a syringe pump. The reservoirs were filled with deionized water, and the device
was stored in a humidified Petri dish until use.
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2.2.4 Immobilization of antibodies on monoliths
To provide analyte specificity, monolithic columns were functionalized with
immobilized antibodies, as illustrated in Figure 2.2.32 Briefly, amine groups were first
introduced on the monolith surface by EDA reaction with the GMA epoxy groups;
neat EDA was flowed into the monolith with a syringe pump (Harvard Apparatus,
Holliston, MA) and incubated at room temperature for 24 h. The monolith was next
washed with 100 mM PBS-EDTA buffer at 10 μL/min for 30 min to remove any
remaining EDA. Pendant amines were reacted subsequently with a heterobifunctional
crosslinker, sulfo-SMCC, which contains an amine-reactive N-hydroxysuccinimide
ester and a maleimide group to react with thiols. Consequently, the sulfo-SMCC can
link reduced antibodies to the amine-modified monolith. The crosslinker was prepared
at 2 mg/mL in PBS-EDTA and was pumped through the monolith at 1 μL/min for 2 h.
Then, 1 mg of anti-FITC was mixed with 200 µL of 6 mg/mL MEA and incubated for
2 h at 37 ºC. MEA preferentially reduces disulfide bonds in the antibody hinge region,
largely leaving the remainder of the antibody intact (see Figure 2.2).33, 34 The partially
reduced antibody was purified using a desalting column (Pierce) equilibrated with
PBS-EDTA. The fractions were monitored by measuring UV absorbance at 280 nm
with a Nanodrop ND-1000 spectrophotometer (Nanodrop Inc., Wilmington, DE).
Once the protein concentration was >10 µg/mL, the solution was pumped into the
monolith and incubated for 4 h at room temperature to attach the antibodies. Unbound
antibodies were washed out using PBS-EDTA, and the devices were stored in PBSEDTA buffer containing 0.02% sodium azide until use.
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Figure 2.2. Protocol for attaching antibodies onto a monolith.

2.2.5 Electrophoresis experiments
FITC labeling of amino acids followed a literature procedure.35 Operation of the
separation chip (Figure 2.1b) has been described previously.25,

36

Briefly,

microchannels were filled with 10 mM carbonate buffer (pH 9.1) containing 0.5%
(w/v) HPC using a syringe pump. The solution in reservoir 3 was removed by pipet
and replaced with 15 μL of sample in running buffer. A platinum electrode was placed
in each reservoir to provide voltage, and all electrodes were interfaced with a custombuilt switch which connected to PS310 (providing 0.6 kV) and PS350 (providing 1.6
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kV) high-voltage power supplies (Stanford Research Systems, Sunnyvale, CA). For
injection, reservoirs 3, 5 and 6 were grounded while reservoir 4 was at 0.6 kV. For
separation, reservoirs 3 and 4 were at 0.6 kV, reservoir 5 was grounded, and reservoir
6 was raised to 1.6 kV. Laser-induced fluorescence was used to detect FITC-tagged
analytes and GFP. The detection system and data collection setup have been reported
before,25 and the sampling rate for data acquisition was 10 Hz; higher sampling rates
may be desirable for quantitative work. Peaks in the electropherograms were
identified by spiking 3 μL of 10-fold more concentrated analyte into reservoir 3 and
repeating the separation under the same conditions.

2.2.6 Characterization and use of Tris-reacted monoliths
To quantitatively monitor sample loading and elution, I used 0.1 mM Trp in Tris
buffer (pH 8.4). Because Trp absorbs at 280 nm, the UV absorbance (Nanodrop ND1000) of the solution eluted from the monolith in reservoir 2 (Figure 2.1a) was
measured. A UV absorbance calibration curve of Trp in Tris buffer (R2=0.991) was
generated to allow quantitation of the Trp eluted from the column. Tris buffer was
first pumped through the monolith to reduce surface wetting losses. Trp solution was
pumped through the monolith, and 50-μL fractions in reservoir 2 were collected in a
0.5-mL microcentrifuge tube. A 2-μL aliquot from each fraction was pipeted onto the
Nanodrop system to probe UV absorbance at 280 nm. Once the UV absorbance
reached a plateau (indicating column saturation), the monolith was rinsed with
deionized water, and 50 μL fractions were collected. To elute Trp from the column,
10 mM phosphate buffer (pH 2.1) was pumped through the monolith, and 20 μL
fractions were collected. The pump rate was 2 μL/min for all steps. The elution
efficiency was calculated by dividing the amount of Trp collected in the elution step
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by the total retained amount of Trp. The quantity of retained Trp was determined by
subtracting the amount of Trp eluted in the loading step from the total amount of Trp
pumped into the monolith.

To evaluate the enrichment achieved with Tris-reacted monoliths, electropherograms
of 200 nM FITC-Asp were obtained before and after monolith extraction. Briefly, a
200-μL sample was separated into two parts. A 100-μL aliquot was pumped through
the Tris-reacted monolith at 2 μL/min and rinsed with 10 μL deionized water. The
retained analyte was then eluted with 20 μL of 10 mM phosphate buffer (pH 2.1). The
pH of the eluted sample was adjusted to ~9 by mixing with 0.4 μL of 1 M NaOH
solution. The monolith-enriched and control samples were subsequently analyzed by
microchip CE as described in section 2.2.5.

2.2.7 Characterization and use of affinity monoliths
The amount of anti-FITC affixed on the monolith was determined by the 280 nm UV
absorbance difference of the antibody solution before and after immobilization.37
Briefly, 500 μL of 10 µg/mL partially reduced antibody solution was separated into
two parts; 250 μL of the solution was used for immobilization and the other 250 μL
were retained as a control. After derivatization, the affinity column was flushed with
10 μL PBS buffer. All solution removed from the column was combined, and the
volume was determined by micropipette. The control antibody solution was diluted to
the same volume with PBS, and the UV absorbance of both solutions was analyzed by
the Nanodrop system.
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Because nonspecific adsorption can cause carryover contamination and decrease
sample loading capacity due to competitive effects, column performance can be
improved if nonspecific adsorption sites are removed. To do so, 40 mg/mL lysozyme
in PBS buffer38 was flushed through the affinity monolith at 2 μL/min for 20 min after
antibody immobilization. Then the affinity column was rinsed with deionized water at
5 μL/min for 10 min to wash out any unbound lysozyme. To examine the
effectiveness of lysozyme treatment for blocking nonspecific adsorption, 50 μg/mL
GFP solutions were used as a fluorescence probe and pumped through both control
and lysozyme-blocked affinity columns. The monoliths were next rinsed with 10 mM
Tris buffer (pH 8.4) at 10 μL/min for 3 min. A ~300-μm-long segment of the affinity
column was illuminated with a laser at 488 nm, and fluorescence images were taken
with a Nikon digital camera (Coolpix 995, Tokyo, Japan).39 Quantitative fluorescence
intensities were monitored by a cooled CCD camera (Coolsnap HQ, Roper Scientific,
Tucson, AZ); the signal was determined from the average intensity on the monolith
for each CCD image. Data processing and CCD parameter adjustments were carried
out using V++ Precision Digital Imaging Software (Version 4.0, Auckland, New
Zealand), and the CCD exposure time was 300 ms.

The extraction efficiency of lysozyme-treated affinity columns was measured
somewhat differently from the Tris-reacted monoliths. FITC-Gly (1 mM) was used as
the indicator, and the concentration of eluted analyte was monitored by CCD. To
quantitatively determine the amount of FITC-Gly, a calibration curve was generated
from the average fluorescence signal of standard FITC-Gly solutions in reservoir 2
(concentration range 0.01-10 mM, R2=0.996).
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To evaluate the selectivity of affinity monoliths, electropherograms of a FITC-amino
acid/GFP mixture were obtained before and after monolith extraction. The procedures
were similar to those described earlier for Tris-reacted monoliths. The mixture
consisted of FITC-Gly, FITC-Phe, FITC-Arg and GFP. All amino acid concentrations
were 10 nM while the concentration of GFP was 50 μg/mL. A 500-μL solution was
separated into two parts: a 50-μL control and a 450-μL monolith-extracted sample.
The 450-μL aliquot was pumped through the affinity monolith at 2 μL/min. The
fractions in reservoir 2 (Figure 2.1a) were collected by micropipette, transferred to
reservoir 3 (Figure 2.1b), and separated by microchip CE. The rinsing, elution, and
pH adjustment were the same as described in section 2.2.6. The monolith-extracted
and control samples were subsequently analyzed by microchip CE as outlined in
section 2.2.5.

a
2.3 RESULTS AND DISCUSSION
2.3.1 Monolith characterization by
SEM
SEM images of a typical monolith in a
microdevice

and

more

detailed

b

monolith features are shown in Figure
2.3. Under my synthesis conditions, the
monolith (see Figure 2.3b) has good
porosity,

which

provides

low

backpressure and a large surface area to
Figure 2.3. SEM images of (a) a typical
monolith in the microchannel and (b)
detailed monolith features.

enhance loading capacity.
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2.3.2 Preconcentration of amino acids on Tris-reacted monoliths
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Figure 2.4. Concentration of Trp collected in reservoir 2 (Figure 2.1a) as a
function of volume flowed through a Tris-reacted monolith at 2 μL/min. Intervals:
(a) loading, (b) monolith saturation, (c) washing, and (d) elution. Fractions in
reservoir 2 were collected at increments of 50 μL in (a-c), and 20 μL in (d).
Fractions were quantified by UV-Vis detection.
A typical concentration profile for Trp over the course of loading, rinsing and elution
from a Tris-reacted monolith is presented in Figure 2.4. Mean recovery volumes were
46 µL for the 50-µL fractions, indicating collection losses of <10%. During the
loading step (Figure 2.4a-b), the Trp concentration in the reservoir after the monolith
was near zero until after 350 µL of flow, and then increased with the flow volume
until the maximum loading of 0.1 mM Trp was reached at around 500 µL (Figure
2.4b). During washing (Figure 2.4c), a small amount of Trp was removed from the
column (<5%), indicating strong Trp retention on the monolith. Over 70% of the
retained Trp was collected in 60 µL of elution buffer (Figure 2.4d). I define the
elution efficiency as the moles of analyte eluted divided by the moles retained. The
average elution efficiency was 82%, the run-to-run variability was 6.1% (n=3), and
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Figure 2.5. Microchip CE of FITC-Asp (a) before and (b) after native monolith
extraction. CE conditions are described in section 2.2.5.
the chip-to-chip variability was 1.2% (n=3). These results demonstrate that monoliths
can be integrated reproducibly in microdevices and have good SPE functionality.

To evaluate the feasibility of combining a monolith column with microchip CE
separation, 200 nM FITC-Asp was loaded onto a Tris-reacted column, eluted and
subsequently separated by microchip CE (Figure 2.5). In comparing the control
(Figure 2.5a) and extracted sample (Figure 2.5b), the retention time of Asp was
about the same, but the peak height of the extracted solution was threefold higher.
Since a 100-μL sample was loaded and elution occurred in a fivefold smaller volume
(20 μL), the threefold signal increase corresponds to ~60% recovery of FITC-Asp.
This type of Tris-reacted column is useful for preconcentration and can be combined
readily with microchip CE, but the extraction and preconcentration is not selective.

2.3.3 Characterization of affinity monoliths
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Under my reaction conditions, the

a

b
amount of anti-FITC immobilized on the
0.5-cm-long

monolith

column

was

250±70 mg/g (n=3). This result is similar
to published data on immobilized trypsin
on a GMA-co-EDMA monolith (~320
mg/g),37 and is somewhat higher than

Figure 2.6. Fluorescence images
of retained GFP on monoliths (a)
without and (b) with lysozyme
blocking.

what was reported using the 1,1’carbonyldiimidazole (CDI) method for

immobilizing anti-FITC on the same monolith (61 mg/g).31 Thus, my protocol yields
comparable results to other methods and has several advantages. Unlike direct
reaction with epoxy groups,40 my technique works with tenfold lower antibody
concentrations (~10 µg/mL) and sixfold shorter reaction times (~4 h). Furthermore,
compared to my approach, the CDI method needs water-free conditions;40 while the
Schiff base and hydrazide techniques involve hydrolysis of the epoxy ring, which
requires catalyst optimization.41

Fluorescence images comparing lysozyme-treated and unblocked monoliths are
shown in Figure 2.6. Considerable GFP was adsorbed on the surface of monoliths not
treated with lysozyme, and bright fluorescence was observed throughout the column.
On the other hand, after lysozyme blocking, very low fluorescence (near background)
was found on the monolith. The ratio of background-subtracted GFP signals in
unblocked and blocked monoliths was 16, indicating that lysozyme passivation
significantly reduces nonspecific protein adsorption on my affinity monoliths.
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Figure 2.7. Microchip CE of amino acids and GFP (a) before and (b) after
affinity column extraction. Peaks 1-5 are Gly, Phe, Arg, FITC, and GFP,
respectively. CE conditions are described in section 2.2.5.
Based on the FITC-Gly CCD signal in reservoir 2 generated as described in section
2.2.7, the average elution efficiency of the lysozyme-treated affinity columns was
86%, and the chip-to-chip variability was 3.1% (n=3). These results indicate that the
elution efficiency of my affinity columns is comparable to that of Tris-reacted
monoliths, and my column performance is reproducible. Importantly, affinity
monoliths have analyte selectivity, as I show in the following section.

2.3.4 Selective extraction by affinity monoliths
To evaluate the selectivity of my affinity columns, a mixture of FITC-labeled amino
acids and GFP was pumped through an affinity monolith and then analyzed by
microchip CE. In Figure 2.7a, the amino acid peak heights were about tenfold smaller
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than GFP. Contrastingly, in Figure 2.7b the GFP peak is reduced significantly after
affinity purification, while the FITC-amino acid peak heights increased around 20fold. Based on the 22-fold reduction in volume during extraction, I calculate a 91%
recovery of FITC-tagged amino acids. The higher recovery in this experiment
compared to Tris-reacted monoliths may be attributed to reduced nonspecific
adsorption with the affinity monolith. After extraction, a FITC peak appeared in the
electropherogram (Figure 2.7b). The FITC peak was identified by spiking 3 μL of
500 nM FITC into reservoir 3 (Figure 2.1b) and repeating the separation under the
same conditions. Uncoupled FITC, which is retained by the affinity monolith, was not
visible above noise in the raw sample (Figure 2.7a). Based on the signal ratio of Arg
to GFP in Figure 2.7a-b, a 25,000-fold reduction in GFP concentration was achieved
after immunoaffinity extraction. My results clearly demonstrate that microchip
affinity monoliths can selectively concentrate and purify target analytes through
specific antibody-antigen interactions.

Pretreatment and selective analyte enrichment are essential in many applications
where the samples are complex, including trace protein analysis. In this chapter,
photo-defined monoliths were applied as sample preconcentrators and affinity
purification columns in polymer microfluidic devices. Successful antibody
immobilization and nonspecific adsorption blocking have also been shown. These
results demonstrate that microchip immunoaffinity monoliths can selectively enrich
desired species in complex biological mixtures for subsequent CE analysis. The good
reproducibility in the amino acid work indicates the excellent potential for use of
these affinity monoliths in fully integrated on-chip sample preparation and separation.
These systems offer the possibility of fast, simple and sensitive protein analysis.
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3. INTEGRATED MICROFLUIDIC DEVICE FOR
SERUM BIOMARKER QUANTITATION USING
EITHER STANDARD ADDITION OR A CALIBRATION
CURVE*

3.1 INTRODUCTION
The two most widely used quantitation tools in traditional analytical chemistry are the
calibration curve and the method of standard addition.1 Micromachined devices for
chemical analysis2,

3

that integrate multiple processes,4 reduce sample and reagent

consumption,5 and decrease analysis time6, 7 and instrument footprint,8, 9 are becoming
an attractive alternative to the classical separation-based analysis approaches.
Although calibration curves have been used in microchip-based chemical analysis,10,
11

the method of standard addition, which is especially desirable for addressing matrix

effects in complex samples such as blood,1 has seen extremely limited use. Very
recently, a serial dilution microfluidic device was applied in standard addition
quantitation of mM concentrations of Fe(CN)64-, a model analyte, although the
aqueous KCl solution was not one for which matrix effects were anticipated.12

Alpha-fetoprotein (AFP) is a diagnostic biomarker for Hepatocellular carcinoma
(HCC),13 with a reported specificity of 65% to 94%.14 In general, patients with an
elevated serum AFP concentration have a higher risk for HCC. Currently, enzyme
linked immunosorbent assay (ELISA) is used in the clinical analysis of AFP in human

*
This chapter is reproduced with permission from Anal. Chem., 2009, 81, 8230-8235. Copyright 2009 American
Chemical Society.
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serum.15 With trained personnel, an ELISA can provide reliable results, although the
microplate format makes ELISA best suited for clinical, rather than point-of-care
(POC) diagnostics. In contrast, rapid analysis6, 7 and the ability to combine multiple
processing steps4,

16

on a single device make a microfluidic-based approach very

attractive for POC AFP analysis. In addition, miniaturized devices can significantly
reduce antigen-antibody reaction time compared with conventional microplate
ELISA.10 The analysis and separation of AFP in spiked buffer solutions in a
microdevice platform have been reported,17-19 and chip-based microfluidic assay
systems for other analytes have been developed for saliva10 and blood samples.11, 20, 21
However, only calibration curve
quantitation has been explored.

Although

previous

antibody-

based monolith work in Chapter 2
has shown promise in selective
extraction for biological mixtures,
off-chip

extraction slows

the

overall

analysis

and

speed

efficiency. To solve this problem,
an affinity column can be coupled
with electrophoretic analysis in a
Figure 3.1. Microchip layout. (A) Design
schematic; reservoirs are (1) rinse, (2) protein
standard, (3) sample, (4) elute, (5) waste, (6)
buffer, (7) inject waste, and (8) high voltage.
The monolith location is indicated by the red
line. (B) Photograph of a fabricated microchip.

single device. The new design
with eight reservoirs is shown in
Figure 3.1. Reservoirs 1-4 were
the inlets for rinse solution, a

58

protein standard, sample, and elution buffer, respectively. Reservoir 5 served as the
waste reservoir during sample preparation. Reservoir 6 contained separation buffer,
reservoir 7 was for injection waste, and reservoir 8 was the separation high-voltage
reservoir. A photograph of a completed microchip is shown in Figure 3.1b. The
poly(methyl methacrylate) (PMMA) microchips were fabricated using a combination
of photolithography, solvent imprinting, and thermal bonding methods described in
Section 2.2.2. The monolith was
also prepared in microchannel
according

to

the

protocol

in

Section 2.2.2.

Figure
electron

3.2

shows

microscopy

scanning
(SEM)

images of a well-defined porous
monolith inside a microfluidic
channel. The polymer is cast
uniformly over the cross section of
the column. These images indicate
that the fabricated monoliths have
appropriate porosity for low back
pressure and sufficient surface area

Figure 3.2. SEM images of monoliths inside
a microfluidic channel. (A) Whole channel
image; (B) magnified view.

for protein immobilization. Antibodies can be directly immobilized on the monolith
surface via reaction between antibody amino groups and epoxy groups on the
monolith surface. Although this protocol needs a higher antibody concentration, it is
simpler and does not require additional reagents such as mercaptoethylamine that are
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needed for the method described in Section 2.2.4. Briefly, the dry monoliths were
sequentially wetted with 2-propanol and running buffer for 5 min each. One mg/mL
anti-FITC in 0.05 M borate buffer (pH 8.0) was loaded into the monolith, and the
microchip reservoirs were filled with buffer to avoid solution evaporation during
reaction. Then, the whole chip was sealed with 3 M Scotch tape (St. Paul, MN) and
put on a shaker at 37 °C for 24 h. Next, any remaining epoxy groups were blocked by
flowing 100 mM Tris buffer (pH 8) through the monolith for 1 h. Finally, the entire
chip was flushed with phosphate running buffer.

In this system, sample loading, rinsing, elution and separation were all performed in
an automated manner by controlling the potentials applied to various reservoirs.
FITC-tagged species were selectively retained by the anti-FITC column and separated
from other contaminants. The retained proteins were then eluted from the monolith
with 200 mM acetic acid.22

The monolith system worked well
for simple systems such as buffered
solution. However, when I applied
real biological samples such as
human serum, significant clogging
was observed in many devices due
to aggregation and non-specific
adsorption of proteins. Thus, I also
explored an open channel column
where antibodies are immobilized on

Figure 3.3. Immunoaffinity extraction overview.
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a patterned section of a microchannel surface to form an affinity column. When a
sample flows through the column, only antigen will be retained based on antibodyantigen interaction, while non-target material will pass through the column to waste
(illustrated in Figure 3.3). This approach has been shown to capture target proteins
from buffer solutions23 in a microdevice, but the ability to work with complex
specimens such as blood, and integrate capture with separation22 has not been shown.

Here, I demonstrate an integrated microfluidic system capable of performing
quantitative determination of AFP, a biomarker for liver cancer,24 in human serum,
using both the method of standard addition and a calibration curve. My approach
utilizes an immunoaffinity purification step coupled with rapid microchip
electrophoresis separation, all under voltage control, in a miniaturized polymer
microchip. These systems with laser-induced fluorescence (LIF) detection can
quantify AFP at ~1 ng/mL levels in ~10 μL of human serum in 30-50 minutes,
offering exciting potential for POC applications.

3.2 MATERIALS AND METHODS
3.2.1 Reagents and materials
Monoclonal anti-AFP antibody, Fluorescein-5-isothiocyanate labeled bovine serum
albumin (FITC-BSA), immunoglobulin G (IgG), dimethyl sulfoxide (DMSO, 99.7%),
glycidyl methacrylate (GMA, 97%), poly(ethylene glycol) diacrylate (PEGDA, 575
Da average molecular weight), and 2,2’-dimethoxy-2-phenylacetophenone (DMPA,
99%) were purchased from Sigma-Aldrich (Milwaukee, WI). Human AFP (>95%)
was from Lee Biosolutions (St. Louis, MO). Green fluorescent protein (GFP, 1.0
mg/mL) was from BD Biosciences (San Jose, CA). Glycine was obtained from ICN
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Biomedicals (Aurora, OH). Sodium phosphate buffer (PBS, pH 7.2) was from Pierce
(Rockford, IL). All solutions were prepared with deionized water (18.3 MΩ-cm)
purified by a Barnstead EASYpure UV/UF system (Dubuque, IA). Poly(methyl
methacrylate) (PMMA, Acrylite FF, 3-mm thickness) was from Cyro Industries
(Rockaway, NJ) and was cut by a CO2 laser cutter (VLS2.30, Universal Laser
Systems, Scottsdale, AZ) before use.

Figure 3.4. Layout of an integrated AFP analysis microchip. (a) Diagram and (b)
photograph of a microfluidic device with integrated affinity column. Reservoir
labels are A: sample, B: rinse buffer, C: elution solution, D: 5 ng/mL AFP standard
solution, E: 10 ng/mL AFP standard solution, F: 20 ng/mL AFP standard solution,
G: 5 mM NaOH (to neutralize the acidic elution solution during injection), H:
waste, and I-L: electrophoresis buffer. Scale bar in (b) is 1 cm.
3.2.2 Affinity column formation
A prepolymer mixture containing GMA as the functional monomer, PEGDA (575 Da
average molecular weight) as the crosslinker, and DMPA as the photoinitiator was
prepared. Before polymerization, the mixture was sonicated in a water bath for 1 min,
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followed by nitrogen purging for 3 min to remove dissolved oxygen. The degassed
mixture (10 µL) was pipetted into reservoir G (Figure 3.4a), filling the microchannel
via capillary action. Next, vacuum was applied to reservoir G to remove most of the
monomer solution, leaving a coating of the prepolymer mixture on the channel walls
(Figure 3.5a-b). The microchip was covered with an aluminum photomask with a
4×4 mm2 opening to provide spatial control of polymerization. The microchip was
then placed on a copper plate in an icebath, and exposed to UV light (200 mW/cm2) in
the wavelength range of 320–390 nm for 5 min (cooling helped minimize undesired
thermal

polymerization).

Finally,

any

unpolymerized

material

was

removed

(d)

(a)

by

flushing 2-propanol through the

(b)

microchannels using a syringe
pump.

To

specificity,
coated

reactive

analyte
polymer

microchannels

derivatized
anti-AFP

provide

with

to

the

previously described procedure
in Section 3.1.22

UV
(c)

were

monoclonal

according

(e)

Figure 3.5. Schematic of preparing a reactive polymer
coating inside a PMMA microchannel. (a) The
microchannel is filled with monomer solution. (b) Bulk
monomer is removed by vacuum. (c) UV initiated
polymerization creates a functional thin-film polymer
coating. (d) SEM image of a microchannel before
coating. (e) SEM image of a microchannel after polymer
coating.

3.2.3 Fluorescently tagged sample preparation
A 3-mL aliquot of fresh human blood was obtained from a healthy volunteer in a 4mL Vacutainer tube (BD) at the Brigham Young University Student Health Center.
The blood sample was centrifuged at 5,000 rpm (Eppendorf 5415C) for 10 min to
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separate the serum from whole blood. FITC and Alexa Fluor 488 TFP Ester
(Invitrogen) were used to label amino acids, proteins, and serum samples using
protocols provided by Invitrogen (MP 00143). Briefly, 0.1 mg fluorescent dye was
dissolved in 10 μL DMSO. For amino acid or protein standards, a 5-μL aliquot of this
DMSO solution was immediately mixed with 0.2 mL of sample (1 mg/mL) in 10 mM
carbonate buffer (pH 9.0). For serum samples, a 2-μL aliquot of DMSO solution with
dissolved dye was mixed directly with 98 μL of human serum. The mixture was
incubated in the dark at room temperature for 24 h (FITC) or 15 min (Alexa Fluor
488). In direct labeling of complex biological specimens, it is essential to have excess
dye to ensure complete labeling.

3.2.4 Data analysis
The calculation of AFP concentration was based on the peak heights in the
electropherograms both for calibration curve and standard addition methods. For the
calibration curve, the AFP peak height from each standard electropherogram was
plotted against the AFP standard concentration to generate a linear calibration curve
by the method of least squares. The AFP concentration in the sample was obtained
from the electropherogram peak height and the calibration curve. The standard
addition method, which effectively eliminates matrix effects,1 was also used to
analyze the AFP samples. Indeed, my protocol of loading sample plus standard on the
affinity column is microfluidically equivalent to spiking standards into a sample in a
classical standard addition analysis. Peak heights from the electropherograms of the
unknown sample, as well as those of the sample plus added standard, were plotted vs.
concentration of added standard. The slope and intercept of this line were calculated
by least squares analysis, and the unknown AFP concentration was given by the
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intercept divided by the slope.1 Standard deviations were calculated from the
regression data.

3.3 RESULTS AND DISCUSSION
I used an acidic phosphate solution (pH ~2) to interrupt the antigen-antibody
interaction and elute target components, which significantly decreased the
fluorescence signal. To characterize this, I put fluorescein (10 μM) in Tris buffer (pH
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Figure 3.6. Electropherograms of fluorescein in different buffers.
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8.3) and in phosphate buffer (pH 2.1) in reservoirs A and C, respectively (Figure
3.4a). In these experiments, affinity columns were not constructed inside the
microchannel. During injection (by applying voltage at reservoir J in Figure 3.4a), the
fluorescence signal was about 10 fold lower for fluorescein in the pH 2.1 solution, as
shown in Figure 3.6. To overcome this issue, I introduced additional reservoir G
(Figure 3.4a) into my microdevices to allow online titration. A 400 V potential was
applied at reservoir J while reservoirs C and G were grounded causing the basic titrant
in reservoir G to neutralize the acidic solution in reservoir C during injection. I used a
CCD camera to monitor the fluorescence signal before and after titration with
different solutions in reservoir G (Figure 3.7). My results indicated that 5 mM NaOH
was the best titrant to enhance the signal from FITC-tagged analytes eluted in low-pH
buffer.

I used a photo-defined immunoaffinity column in a polymeric microdevice to extract
AFP from blood serum. Retained AFP was eluted through an injection cross and
rapidly analyzed by microchip electrophoresis. To quantify the serum AFP
concentration precisely, both standard addition and calibration curve functions were
integrated into the chip. Importantly, all fluid control on-chip was carried out via
voltages applied to reservoirs, facilitating automation. The fabrication protocol for
poly(methyl methacrylate) (PMMA) microdevices was adapted from Section 2.2.2.22,
25

The layout of my integrated AFP analysis microchip is shown in Figure 3.4a, and a

device photograph can be seen in Figure 3.4b. PMMA itself is relatively inert toward
direct chemical reaction, which necessitates making a photo-defined polymer on the
microchannel surface to immobilize antibodies. The thickness of the reactive polymer
formed on the channel surface was ~3 μm based on SEM images (Figure 3.5d-e).
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Figure 3.8. Schematic diagram of operation of the microchip with integrated affinity
column. (a) Sample loading, (b) standard loading, (c) rinsing, (d) injection, and (e)
separation.
To quantify the AFP concentration in serum samples, both calibration curve and
standard addition methods were used to validate the accuracy and precision of
microchip performance. The voltage configurations and flow paths during operation
of the microchip (described below) are shown in Figure 3.8. For the calibration curve,
each AFP standard solution was loaded on the affinity column for 5 min by applying
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voltage between either reservoir D, E, or F and reservoir H; the column was rinsed
with PBS buffer for 5 min by applying a potential between reservoirs B and H;
analyte was eluted/injected with a voltage applied to reservoir J while grounding
reservoirs C and G for 45 s using phosphoric acid/dihydrogen phosphate solution at
pH 2.1; and then loaded material was separated by microchip electrophoresis using a
potential between reservoirs I and L. The sample was analyzed by loading on the
affinity column for 5 min with voltage applied between reservoirs A and H, and then
rinsing, elution/injection and separation were done the same as with the standards. For
the standard addition method, after loading sample on the affinity column for 5 min as
above, one standard was loaded
on the affinity column for 5
(a)

min as before, followed by

1

rinsing, elution/injection and
electrophoresis

separation, the same as for the
calibration curve. This process
was then repeated for each
standard. LIF was used to
detect the labeled AFP during
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Figure 3.9. Microchip CE of a mixture (a) before and
(b) after affinity column extraction. Peaks 1-5 are
FITC-Gly, GFP, FITC-BSA, FITC-AFP, and FITCIgG, respectively.

suitability for POC assays.
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To demonstrate the integration of immunoaffinity extraction with microchip
electrophoresis on a microdevice, a mixture of non-target fluorescent compounds
along with FITC-AFP was loaded through an affinity column and then analyzed. Five
peaks were observed before extraction, as shown in Figure 3.9a; I note that FITCBSA and FITC-AFP have similar elution times, and are not baseline resolved in the
electropherogram. Contrastingly, after on-chip affinity purification (Figure 3.9b), all
non-target peaks are essentially eliminated, while only the AFP peak remains.

Figure 3.10. FITC-labeled human serum, run by microchip electrophoresis (a)
before and (b) after integrated affinity column extraction.

Importantly, similar device performance was observed with a much more complex,
fluorescently labeled human serum sample. Microchip electrophoresis of FITC-tagged
human serum (Figure 3.10a) showed numerous overlapping peaks before extraction,
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precluding facile AFP determination. On the other hand, after on-chip AFP extraction,
a single, clear peak corresponding to AFP was observed in microchip electrophoresis
(Figure 3.10b). The integrated immunoaffinity extraction step resulted in a ~5,000fold reduction of non-target protein signal, and enabled detection of the AFP “needle”
in the serum “haystack”. I estimate that the AFP sample is >95% pure after
immunoaffinity extraction, based on target to spurious peak ratios in the
electropherograms in Figure 3.10. These results clearly indicate that my approach can
selectively purify target analytes from very complex mixtures. A typical affinity
column can perform well for at least a few tens of replicate runs.
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Figure 3.11. CBQCA labeling reaction.
such

as

proteins;

however, the room-temperature reaction kinetics (~24 h), make this label less
desirable for POC work. I tried two different fluorescent dyes to shorten the labeling
process: 3-(4-carboxybenzoyl)quinoline-2-carboxaldehyde (CBQCA) and Alexa Fluor
488 TFP Ester (both from Invitrogen, Eugene, OR). Unconjugated CBQCA (Figure
3.11) doesn’t fluoresce, and it can label proteins in several seconds, making this dye
very well suited for POC work. However, CBQCA-labeled AFP generated relatively
low fluorescence signal and a broad peak (Figure 3.12). In addition, potassium
cyanide, a highly toxic substance, is used in the labeling process. The need for
extreme care in handling is not ideal for clinical use.
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Figure 3.12. 1 μg/mL CBQCA-AFP run by microchip electrophoresis.
On the other hand, I found that Alexa Fluor 488
SO3

SO3
H2N

O

+
NH2

TFP Ester (Figure 3.13) completely labeled AFP
in ~30 min (Figure 3.14 and Table 3.1), making

COO

this dye very attractive for a POC assay. The
O
F

F

F

F

labeling process can be further sped up at 37 °C
(Figure 3.15).

Figure 3.13. Structure of
Alexa Fluor 488 TFP Ester.
For some microchip bioassays, sample and standards share the same reservoir,10, 28
requiring a cleaning step during analysis, which hampers the ability to automate for
POC assays. In my design, sample and standard reservoirs are integrated on the
microdevices. Finally, although previous systems have only used calibration curves to
quantify biomarkers,10, 11 my format enables both standard addition and calibration
curve protocols to be performed on-chip.

71

Fluorescence Signal
15

20

25

30

35

40

45

Time (s)

Fluorescence signal

Figure 3.14. Dynamic labeling of AFP with Alexa Fluor 488 TFP Ester at room
temperature. Traces are black: labeling 5 min, red: 10 min, green: 15 min, blue: 20
min, light blue: 30 min, orange: 60 min, and pink: 120 min. The unattached label
migrates at ~23 s, and the AFP peak is at ~32 s.
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Figure 3.15. Dynamic labeling of AFP with Alexa Fluor 488 TFP Ester at 37 oC.
Traces are black: 5 min red: 10 min, green: 15 min, blue: 20 min, light blue: 30 min,
and pink: 60 min. The unattached label migrates at ~18 s, and the AFP peak is at
~23 s.
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Table 3.1. Peak heights of AFP in dynamic labeling with Alexa Fluor 488 TFP
Ester (derived from Figures 3.14 and 3.15).
Labeling time (min)

AFP Peak Height

AFP Peak Height

(arb. units, 25 °C)

(arb. units, 37 °C)

5

0.0060

0.0041

10

0.0116

0.0085

15

0.0174

0.0185

20

0.0209

0.0238

30

0.0244

0.0235

60

0.0258

0.0209

120

0.0258

I used my integrated microdevices to quantify AFP concentration in human serum
using either a linear calibration curve (Figure 3.16a, c) or the standard addition
method (Figure 3.16b, d). Both approaches yielded reproducible microchip
electrophoresis data (Figure 3.16a, b) with concentration-dependent peak heights
(Figure 3.16c, d). AFP concentrations and standard deviations determined both by
calibration curve (4.1±0.9 ng/mL) and standard addition methods (4.6±0.9 ng/mL)
were internally consistent. Calculation details can be found in Section 3.2.4. To
further evaluate my approach, different amounts of AFP were spiked into human
serum, and these samples were then labeled with Alexa Fluor 488 TFP Ester. In either
calibration curve or standard addition protocols, the standard concentration should be
close to the sample concentration for optimal accuracy and precision. However, in
POC

screening

the

AFP

concentration
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is

initially

unknown.

Figure 3.16. Integrated calibration curve and standard addition quantification of AFP
in human serum. (a) Microchip CE of Alexa Fluor 488 labeled human serum and of
AFP standard solutions after affinity column extraction. Curves are: black-unknown
human serum sample, red-5 ng/mL standard AFP, green-10 ng/mL standard AFP, and
blue-20 ng/mL standard AFP. (b) Microchip CE of Alexa Fluor 488 labeled human
serum after standard addition and affinity column extraction. Traces are: blacksample, red-sample+5 ng/mL standard AFP, green-sample+10 ng/mL standard AFP,
and blue-sample+20 ng/mL standard AFP. (c) Calibration curve generated from (a),
with unknown sample data point indicated with a star. (d) Standard addition plot of
concentration of standard added vs. peak height generated from (b).
Because the action threshold for serum AFP is 20 ng/mL,15,

29

I set the standard

concentrations to 5, 10 and 20 ng/mL in my protocol for optimal precision in the
diagnostic range. The AFP concentrations measured in my microdevices using both
calibration curve and standard addition methods were compared with values measured
by a commercial ELISA kit (Figure 3.17). In general, both calibration curve and
standard addition results matched ELISA results well (Figure 3.17 and Table 3.2).
Because the AFP standard concentrations were optimized for the 20 ng/mL diagnostic
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threshold, higher AFP concentrations (>50 ng/mL) had lower accuracy and precision;
however, a POC assay that reports a concentration well above the action level would
require more thorough subsequent clinical analysis.

Table 3.2. Results from the integrated microfluidic AFP assay.*
Spiked AFP

ELISA

Calibration curve

Standard addition

(ng/mL)

(ng/mL)

(ng/mL)

(ng/mL)

unknown 1

250

110.4±2.7

126±6.8

198±41

unknown 2

100

55±2.1

52±1.1

64±8.8

unknown 3†

0

2.8±2.0

4.1±0.9

4.6±0.9

unknown 4

750

323.6±6.7

313±41

1050±520

unknown 5

50

49.3±2.0

29.4±0.1

33.2±2.7

unknown 6

300

205.1±4.3

165±25

169±82

*The number that follows the ± sign is the standard deviation.
†

The blank concentration is ~4 ng/mL.

Although my microdevices have been designed for AFP analysis, this approach is not
limited to just AFP. These microchips could be easily adapted for detection of other
biomarkers by simply immobilizing different antibodies in the affinity column.
Moreover, it should be possible to attach multiple antibodies targeting different
analytes to the same column, allowing multiplexed, simultaneous biomarker detection,
which I next show in Chapter 4. My system shows great promise for rapid
quantitation of biomarkers in a POC setting, which should be of considerable value in
early stage disease diagnosis.
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Figure 3.17. Accuracy and precision data for integrated microfluidic AFP assay.
Red: spiked concentration, green: measured by ELISA, blue: measured by
calibration curve, and light blue: measured by standard addition. Error bars indicate
± one standard deviation.
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4. MICRODEVICES INTEGRATING AFFINITY
COLUMNS AND CAPILLARY ELECTROPHORESIS
FOR MULTI-BIOMARKER ANALYSIS IN HUMAN
SERUM *

4.1 INTRODUCTION
Due to early stage diagnosis and advances in cancer treatment, the five-year relative
survival rate (of patients compared with controls) for all cancers has improved from
50% in 1975-1977 to 66% in 1996-2004.1 Presently, cancer diagnosis is based mainly
on morphological examination of a tumor biopsy, which is expensive, time consuming,
and, hence, low in throughput.2 As an earlier stage tool, biomarkers can play an
important role in cancer screening, diagnosis, and recurrence detection.3,

4

For

instance, prostate-specific antigen (PSA) is a widely used analyte for prostate cancer
screening.5 However, an abnormal level of a single biomarker alone is not generally
sufficient to diagnose cancer.6 Thus, many men with PSA levels less than the 4.0
ng/mL action threshold had prostate cancer detected by biopsy (i.e., false-negatives).7
Furthermore, PSA levels above 4 ng/mL are associated with other conditions such as
prostatitis, reducing the specificity (i.e., false-positives).5 To overcome these
shortcomings, simultaneous detection of multiple markers8 would enable more
sensitive and accurate cancer screening with higher throughput. For instance, Yang et
al.9 evaluated 12 biomarkers for gastrointestinal cancer diagnosis, and a combination
of five markers significantly improved the diagnostic rate to ~40% relative to the

*
This chapter is reproduced with permission from Lab on a Chip, 2010, DOI:10.1039/C005288D. Copyright 2010
Royal Society of Chemistry.
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~27% rate achieved with just carcinoembryonic antigen (CEA).

Currently, most biomarkers are detected via immunoassays such as enzyme linked
immunosorbent assay (ELISA).10 Recently, Ladd et al.11 developed a label-free
detection protocol for cancer biomarker candidates using surface plasmon resonance
imaging, with a limit of detection as low as a few ng/mL. Unfortunately, significant
nonspecific adsorption was observed in diluted serum analysis, which led to a high
background and much poorer detection limit. A recent review summarizes the
advances and challenges of multiplexed immunoassay platforms.12 However, these
multimarker systems need further validation and quality control. Transferring these
approaches to a microfluidic format could provide higher speed and lower reagent
consumption.13 Yet, analyzing real samples in complex matrices using microdevices
is challenging because the small microchip platform reduces resolving power and
peak capacity relative to full-size instruments.14 Furthermore, due to small injected
sample volumes and a short optical path, the concentration detection limit in
microchips is often higher than in conventional techniques.15 To overcome these
shortcomings of microfluidic systems, multiple analysis functions can be integrated
on a single device, enabling sample purification and preconcentration.16 Many
processing steps including sample desalting,17 labeling,18 and extraction19 have been
successfully performed in microchip systems. Because extraction can purify target
components from complex matrices, it is an especially attractive technique for the
pretreatment of real samples.

Solid phase extraction (SPE) is used heavily in sample purification. The principle of
SPE is as follows: the targeted component (or components) is retained on a solid
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medium to separate it from the matrix, and retained materials can then be eluted for
analysis. SPE has been applied successfully in a microfluidic format;20, 21 however,
nonspecific interactions like hydrophobic absorption alone do not provide high
selectivity. To circumvent this shortcoming, enzymes or antibodies can be
immobilized on the solid surface.21, 22 For instance, pisum sativum agglutinin has been
immobilized on monolithic substrates to retain glycoproteins, which can be eluted in
several fractions based on their affinities.23 A recent review summarizes the
application of immunoaffinity capillary electrophoresis (CE) for biomarker, drug and
metabolite analysis in biological samples.24 These studies indicate a promising future
for immunoaffinity extraction as a pretreatment method for biological specimens in
microdevices. In Chapter 3, I demonstrated an integrated microfluidic system that
coupled immunoaffinity extraction with rapid microchip CE separation for
quantitation of alpha-fetoprotein (AFP) in human blood serum, using either standard
addition or a calibration curve for determining concentrations.19 Although this method
was effective at quantifying AFP, the affinity column properties were not fully
characterized, and only one biomarker was detected.

Here I demonstrate an integrated microfluidic system that can simultaneously quantify
multiple cancer biomarkers in human blood serum. I selected four commercially
available biomarkers as test proteins (Table 4.1).25-28 These four biomarkers were
chosen more for their separation characteristics than their combined clinical
relevance. Antibodies were attached to microchip columns, and the amounts of
immobilized antibodies were characterized. I used my integrated microdevices to
quantify these four proteins at low ng/mL levels, which are in the range of their action
thresholds in human blood serum. These results demonstrate that my platform is
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generalizable and applicable for the simultaneous quantification of multiple
biomarkers in complex samples.
Table 4.1. Properties of the cancer biomarkers detected in this study.
Biomarker

Clinical use

Normal level

Action threshold

(ng/mL)

(ng/mL)

AFP25

liver cancer marker

<10

20

CEA26

colorectal cancer marker

<5

20

Cytochrome C

prognostic marker during

<0.5

25

(CytC)27

cancer therapy

Heat shock protein

many oncogenic proteins

n/a

Overexpression

90 (HSP90)28

are HSP90 clients

(no action threshold)

4.2 MATERIALS AND METHODS
4.2.1 Reagents and materials
CytC (from bovine heart), CEA (from human fluids), monoclonal anti-AFP antibody
(produced in mouse), monoclonal anti-CEA antibody (produced in mouse), anti-CytC
antibody (produced in sheep), glycidyl methacrylate (GMA, 97%), poly(ethylene
glycol) diacrylate (PEGDA, 575 Da average molecular weight), and 2,2-dimethoxy-2phenylacetophenone (DMPA, 99%) were purchased from Sigma-Aldrich (St. Louis,
MO). HSP90 and monoclonal anti-HSP90 antibody (produced in mouse) were
obtained from Stressgen (Ann Arbor, MI). AFP was from Lee Biosolutions (St. Louis,
MO). Human blood serum from a healthy male (Sigma-Aldrich) was spiked with
different concentrations of AFP, CytC, CEA, and HSP90 in the range of 20 to 250
ng/mL (all above normal clinical levels). These unknown serum samples were then
labeled with Alexa Fluor 488 TFP Ester (Invitrogen, Eugene, OR) following an
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Invitrogen protocol (MP 00143). Briefly, 0.1 mg fluorescent dye was dissolved in 10
μL dimethyl sulfoxide (DMSO), and a 2-μL aliquot of DMSO solution was mixed
with 98 μL of spiked human serum. The mixture was left to react in the dark at room
temperature for 15 min. For protein standards, a 5-μL aliquot of the DMSO solution
containing the fluorescent label was mixed with 0.2 mL of 1 mg/mL protein in 10 mM
carbonate buffer (pH 9.0). All solutions were prepared with deionized water (18.3
MΩ-cm) purified by a Barnstead EASYpure UV/UF system (Dubuque, IA).
Poly(methyl methacrylate) (PMMA, Acrylite FF) was purchased from Cyro Industries
(Rockaway, NJ) and was cut into 4.0 × 5.5 cm2 blanks using a CO2 laser cutter
(VLS2.30, Universal Laser Systems, Scottsdale, AZ) before device fabrication.

4.2.2 Layout and fabrication of microfluidic devices
The device layout (Figure 4.1) and fabrication protocols were adapted from Chapters
2 and 3.19,

29

Briefly, the microchips contained a sample reservoir (1), two SPE

processing reservoirs (2-3) for wash buffer and elution solution, respectively; three
reservoirs (4-6) having different standard concentrations for quantification; a waste
reservoir (8) for the immunoaffinity extraction step; a reservoir (7) for basic solution
(5 mM NaOH) to neutralize the acidic elution solution; and three reservoirs (9, 10 and
12) for standard microchip CE separation. The additional reservoir 11 was originally
designed to facilitate the integration of a semi-permeable membrane near the injection
intersection, but this capability was not utilized in the present experiments. The
microchip pattern was transferred to silicon template wafers using photolithography
and wet etching.29 PMMA substrates (1.5-mm thick) were imprinted by hot
embossing against the etched Si templates.21 The patterned PMMA was thermally
bonded to an unimprinted PMMA substrate (3.0-mm thick, to provide ~10 μL
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(a)

(b)

Figure 4.1. Layout of an integrated microdevice. (a) Schematic diagram and (b)
photograph of a typical microchip with integrated affinity column. See the text for
reservoir descriptions.
reservoir volume capacities) with laser-cut holes (2.0-mm diameter). Channel widths
were ~50 µm, except the affinity column which was 100-µm wide, and channel
depths were ~20 µm.

Since PMMA is inert to many chemical reactions, the microchannel surface was
coated to form affinity columns. Briefly, a prepolymer mixture containing GMA
(~60%), PEGDA (~40%), and DMPA (0.5%) was sonicated and then purged with
nitrogen for 3 min to remove dissolved oxygen. The degassed mixture was introduced
into the affinity microchannel region via reservoir 7, and a ~3 μm coating of the
prepolymer mixture remained on the channel walls after applying vacuum to reservoir
7 and flowing nitrogen (~50 psi) from reservoir 1. The microchip was covered with an
aluminum photomask, placed on a copper plate in an icebath, and exposed to UV light
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(320–390 nm, 200 mW/cm2) for 5 min. Finally, unpolymerized material was removed
via flushing of 2-propanol through the microchip using a syringe pump.

For immobilization on the patterned affinity channel surface, the four antibodies (antiAFP, anti-CEA, anti-CytC and anti-HSP90) were mixed at 0.5 mg/mL each in 50 mM
borate buffer (pH 8.6). The antibody mixture was pipetted into reservoir 8 and the
affinity column filled via capillary action. Borate buffer was placed into all other
microchip reservoirs to avoid evaporation during reaction. The entire chip was sealed
with 3M Scotch tape (St. Paul, MN), and the mixture was left to react at 37 °C for 24
h in the dark.30 After reaction, the device was flushed using 100 mM Tris buffer (pH
8.3) for 0.5 h. This process also blocked any remaining epoxy groups on the column.
Finally, the entire chip was rinsed with carbonate buffer (pH 9.1) before use.

4.2.3 Laser-induced fluorescence (LIF) detection setup
LIF detection was performed on a Nikon Eclipse TE300 inverted optical microscope
equipped with a photomultiplier tube (PMT) detector (Hamamatsu, Bridgewater, NJ)
and CCD camera (Coolsnap HQ, Roper Scientific, Sarasota, FL). The LIF detection
system and data collection setup have been described in Section 2.2.5.21,

29

CCD

images were collected at 10 Hz and analyzed using V++ Precision Digital Imaging
software (Auckland, New Zealand). The sampling rate for PMT detection was 20 Hz.

4.2.4 Characterization of affinity columns
To estimate the saturation point of affinity columns, different concentrations of
fluorescently labeled AFP were loaded for 5 min by applying 400 V at reservoir 8 and
0 V at reservoir 1. Then, unbound AFP was rinsed off the affinity column with PBS
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buffer for 3 min with 400 V applied to reservoir 8 while grounding reservoir 2. The
fluorescence signal on the affinity column was monitored via CCD during the loading
and rinsing processes (Figure 4.2).

loading

800

rinsing

CCD signal (arb. units)

700
600
500
400

AFP
HSP90
CEA
Cyt C

300
200
100
0
0

100

200

300

400

500

600

Time (s)
Figure 4.2. Fluorescence signal from the affinity column during loading and rinsing
steps. All points are average values from CCD images, and standard deviations (not
shown, ~200 units) were calculated from ~32,000 pixels in the CCD images. The
relative standard deviation values reflect some heterogeneity in the density of
immobilized antibodies on the column, as well as minor imperfections on the
PMMA surfaces from device bonding.

For each analyte, standards of different concentrations were loaded into a
microchannel, and fluorescence signal versus protein concentration plots were
generated. These calibration curves provided the relationship between CCD signal and
the concentration of fluorescently labeled protein in the column in Figure 4.3. To
determine the amount of immobilized antibodies on the affinity column, 1 μg/mL
biomarker standards were loaded on the column with 400 V between reservoirs 1 and
8 for 330 s to saturate all active antibody sites, and the column was washed with Tris
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buffer using 400 V between reservoirs 2 and 8 for 210 s to remove unbound material.
CCD images of the affinity column were recorded at 10 s intervals for the first 60 s,
and then 30 s intervals for the remaining time during the loading and washing
processes. The CCD signal after washing corresponded to column saturation with
antigen; this signal was converted into the equivalent antigen concentration in the
column based on the obtained calibration curves. From the column volume of 6 nL
(length: 3 mm), I determined the mass of each protein bound on-chip at saturation.
Then, assuming the antigen-antibody interaction occured with a 1:1 molar ratio, the
quantity of immobilized antibodies on the column was determined.

1600

CCD signal (arb. units)

1400

AFP
HSP90
CEA
CytC

1200
1000
800
600
400
200
0
0

200

400

600

800

1000

Protein concentration (ng/mL)
Figure 4.3. Relationship between background subtracted CCD signal and
concentration of fluorescently labeled proteins. Error bars indicate standard
deviations (n = 3).

4.2.5 Immunoaffinity extraction and electrophoretic separation
The operation of my integrated microchips and the data analysis were adapted from
Section 3.2.4.19 To demonstrate proof-of-principle of multiplexed operation, a mixture
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of fluorescently labeled AFP, CytC, CEA and HSP90 in buffer was compared before
and after microchip immunoaffinity extraction. A double-T microchip layout29 was
used to directly separate the mixture (without immunoaffinity extraction). The
mixture was then pipetted onto an integrated microdevice, loaded for 5 min on the
affinity column, rinsed for 5 min, eluted through the injection intersection for 45 s,
and then separated by microchip CE.

For calibration curve quantitation, each standard solution containing all four proteins
was loaded on the affinity column (5 min), rinsed with PBS buffer (5 min), eluted
through the injection intersection for 1 min with phosphate buffer (pH 2.1), and
separated by microchip CE, by applying a sequence of potentials to the various
reservoirs for all steps as in Section 3.3.19 The sample was analyzed by loading it on
the affinity column, rinsing, eluting/injecting and separating the same as for the
standards. The peak heights from each standard electropherogram were plotted against
the series of known protein concentrations, and linear regression was used to fit a line
to the data. The concentration of each component in the sample was calculated from
its peak height in the electropherogram and the linear fit equation.

For standard addition quantification, sample was first analyzed the same way as for
the calibration curve. Next, sample was loaded on the affinity column for 5 min,
followed by loading of the first standard mixture for 5 min; the rinsing,
elution/injection and microchip CE separation steps were then carried out as before.
This same set of processes was repeated to spike the other two standards into the
sample and analyze them as in Section 3.3.19 A linear fit was generated from the peak
heights in the electropherograms of the unknown sample and of the sample spiked
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with standards, plotted against the standard concentrations spiked into the sample. The
concentration of each protein was calculated from the intercept and slope of this line.

4.3 RESULTS AND DISCUSSION
4.3.1 Characterization of affinity columns
The fluorescence signal on affinity columns in my microdevices, as a function of AFP
concentration is shown in Figure 4.4. The relationship between CCD signal and AFP
concentration was linear up to ~500 ng/mL, and the signal approached a plateau at 1
µg/mL. Above ~1 µg/mL AFP, the antibody sites were all occupied with fluorescently
labeled AFP (column saturation), such that the fluorescence signal did not change
with further AFP concentration increases. Thus, after loading ~1 µg/mL of a target
protein on the affinity column and washing off unbound material, the maximum
amount of retained antigen can be monitored, as shown in Figure 4.2. During the
rinsing step, the fluorescence signal decreased by ~15% due to the removal of some
unbound protein. Importantly, the signal remained stable after this initial decline
during rinsing, indicating strong interaction between antigens and antibodies. In
addition, the fluorescence signals of all four proteins were in the same range after
rinsing, indicating that the derivatization reaction had little bias toward any of the four
antibodies I used.
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Figure 4.4. Background-subtracted fluorescence signal on a typical affinity column
after washing, for multiple AFP concentrations. The lower concentration points are
expanded in the inset.

Calibration curves relating fluorescence signal and standard protein concentration
(Figure 4.3) converted the CCD signal into the effective concentration of
fluorescently labeled protein attached to the column at saturation. For all four proteins,
the CCD signal had a linear relationship with protein concentration (R2 > 0.95). The
difference in mass per volume sensitivity for the various analytes is due to molecular
differences in terms of number of available fluorescent labeling sites and molecular
weight. Based on the CCD signal during the rinsing step (Figure 4.2) and the 6-nL
column volume, the amounts of retained proteins on the affinity column were
determined (Figure 4.5). The retained protein amounts were all in the range of 2 to 7
pg, and were also consistent from chip to chip, indicating that immunoaffinity
extraction is not affected adversely by multiplexing antibodies on the column. There
was a 10–30% between-device variability in the amount of retained proteins, due to
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Figure 4.5. Amounts of retained proteins on the affinity columns in three different
microdevices. Standard deviations were calculated from the regression data in
Figure 4.3.
small differences in column surfaces and operation conditions. Importantly, since
samples and standards are both analyzed on the same column, any minor betweendevice differences have no effect on quantitation. Assuming the antigen-antibody
interaction occurs with a 1:1 molar ratio, the average amounts of immobilized antiAFP, anti-CEA, anti-CytC, and anti-HSP90 were 60, 30, 190, and 45 amol,
respectively (~0.1 nmol/m2). My channel wall coated affinity columns have a lower
density of immobilized antibodies than high surface area, porous beads (2–35
nmol/m2).31 Since submicroliter volumes of sample are loaded on my affinity columns,
the present binding capacity is not a serious issue for trace (<μg/mL) biomarker
analysis. In addition, the density of binding sites in my devices can be easily increased
by using a porous material as the solid support. These results demonstrate that affinity
columns with four antibodies can be integrated reproducibly in my microdevices with
good functionality.
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4.3.2 Separation of a model protein mixture
To demonstrate the feasibility of integrated microchip immunoaffinity extraction and
CE for multiple biomarker analysis, a mixture of Alexa Fluor 488-labeled AFP, CytC,
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Figure 4.6. Alexa Flour 488-labeled biomarker mixture (1 μg/mL for each protein),
run by microchip electrophoresis (a) before and (b) after integrated affinity column
extraction.
HSP90 and CEA at 1 µg/mL each in carbonate buffer was analyzed. Five baselineresolved peaks, including a significant fluorescent dye peak, were observed when this
mixture was analyzed by standard microchip CE (without affinity extraction), as
shown in Figure 4.6a. On the other hand, Figure 4.6b shows the electropherogram
after this mixture was loaded on an affinity column having the requisite antibodies
and then separated by microchip CE after rinsing and elution/injection. With on-chip
affinity purification, the dye peak was essentially eliminated (over 10,000-fold
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reduction), while the four biomarker peaks remained. In addition, the HSP peak was
sharpened after extraction because of the removal of a co-eluting impurity from the
sample. These results indicate that my integrated microdevices can selectively retain
and analyze targeted compounds in samples.
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Figure 4.7. Microchip CE of Alexa Fluor 488-labeled human serum and of standard
solutions after affinity column extraction. Curves are: black—unknown spiked
human serum sample, red—5 ng/mL standard mixture, green—10 ng/mL standard
mixture, and blue—20 ng/mL standard mixture.

4.3.3 Multiplexed biomarker quantitation in human serum
To assess the ability of my approach to quantify biomarkers in real samples, I
analyzed a series of human blood serum specimens that had been spiked with four
proteins and fluorescently tagged with Alexa Fluor 488 TFP Ester. Spiked biomarker
concentrations in human serum were determined in the integrated affinity extraction
and microchip CE devices using either a linear calibration curve (Figure 4.7) or the
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standard addition method (Figure 4.8). In Figure 4.7, the peak heights of standards
increased proportionally going from 5 ng/mL to 20 ng/mL, and the peak heights
increased with spiked protein concentration in Figure 4.8. In all electropherograms

Fluorescence signal (arb. units)
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Figure 4.8. Microchip electrophoresis of Alexa Fluor 488-labeled human serum
after standard addition and affinity column extraction. Curves are: black—unknown
spiked human serum sample, red—serum sample + 5 ng/mL standard mixture,
green—serum sample + 10 ng/mL standard mixture, and blue—serum sample + 20
ng/mL standard mixture.
were observed, indicating the efficacy of the multiplexed immunoaffinity extraction
column. I tested four spiked human blood serum samples, and the calibration curve
and standard addition results overall matched the known spiked concentrations well
(Table 4.2). In general, the standard deviations for the calibration curve were smaller
than those for standard addition; quantitation by standard addition involves
extrapolation, which may partially explain the higher standard deviations. Because I
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Table 4.2. Results from a blinded study with the integrated microfluidic
biomarkers assay chip for spiked human serum samples (all concentrations are
ng/mL).

Analyte

HSP90

AFP

CytC

CEA

Concentration

Sample
number

Spiked

1

Standard deviation

Calibration Standard Calibration Standard
curve

addition

curve

addition

110

116

87

7

7

2

183

200

140

13

94

3

219

206

201

13

31

4

58

73

60

4

12

1

116

106

128

7

5

2

140

136

166

10

35

3

37

27

50

2

13

4

70

63

92

4

12

1

200

152

156

25

37

2

53

38

22

5

3

3

106

104

142

16

42

4

160

118

128

19

27

1

27

38

42

2

8

2

50

60

50

4

7

3

83

95

131

6

21

4

100

118

136

8

8

eliminated the serum matrix in the affinity purification step, the results were similar
for the calibration curve compared to standard addition, which is most effective in
complex mixtures. The total analysis time for these samples (including labeling) was
<60 min; therefore, the integrated devices are well suited for point-of-care (POC)
applications. To verify the ability of these microchips to quantify biomarkers at native
levels, I also analyzed an unspiked serum sample (Table 4.3). The biomarker
concentrations are all <6 ng/mL, indicating that this system works effectively with
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naturally produced biomarkers at trace levels. The calibration curve method provided
more reliable and precise results than standard addition in these analyses.

Table 4.3. Results for an unspiked human serum sample with the integrated
microfluidic biomarkers assay chip (all concentrations are ng/mL).
Concentration
Analyte

Standard deviation

Calibration

Standard

Calibration

Standard

curve

addition

curve

addition

HSP90

5.6

0.4

0.9

2.0

AFP

3.5

1.9

0.1

1.0

CytC

3.5

0.9

1.9

1.3

CEA

3.6

4.9

0.1

0.2

My approach could be easily extended up to ~10 biomarker detection by simply
immobilizing more antibodies on the affinity column. The surface area of my open
channel affinity column (i.e., column saturation) could be an obstacle to scaling to
tens of biomarkers, although I note that the column saturation level is a factor of at
least 25 above the diagnostic threshold for my markers. Furthermore, the binding
capacity could be raised by increasing the surface area of columns (e.g., using a
monolith material as the solid support). For more than ~10 components, the peak
capacity in my present device design could be an issue, but a longer folded separation
channel32 (e.g., 8-cm length) could increase the peak capacity to ~30. Peak capacity
could also be raised through spectral multiplexing, wherein several distinct
fluorescent labels are used on different proteins. Thus, higher-level multiplexing
should be able to significantly increase the number of biomarkers that can be
quantified.
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To make a real POC assay, the LIF system and power supplies would need to be
miniaturized. A shoebox-size LIF package has been successfully demonstrated for
microchip CE analysis of DNA, indicating strong potential to miniaturize the platform
for POC applications.33 In addition, post-column labeling could be used to decrease
the labeling time and reduce operator intervention.18 I further note that device
throughput could be increased by performing separations in parallel,15 with multiple
extraction and separation units on a single chip. Such integrated capillary array
devices would enable either replicate sample analysis or higher-level multiplexing.

4.4 CONCLUSIONS
Sample pretreatment, cleanup, and quantitation are essential in biomarker analysis in
complex media. In this study, affinity purification columns with four different
antibodies were prepared in polymer microfluidic devices. The amounts of antibodies
immobilized on my columns were consistent from chip to chip, and comparable, midattomole amounts of each of the four antibodies were attached to the columns.
Analysis of four proteins in buffer solution demonstrated that multiplexed
immunoaffinity columns could selectively extract the desired species for subsequent
CE analysis. With spiked human blood serum samples, four proteins in the ng/mL
range were simultaneously quantified using both calibration curves and standard
addition. In general, the calibration curve and standard addition results were close to
the known spiked concentrations. These microdevices provide an excellent platform
for fast, integrated and automated biomarker quantitation. I note that for clinical
applications, the device-to-device and run-to-run variability should be further
characterized. Furthermore, my system could be expanded to ~30 biomarker
quantitation by immobilizing additional different antibodies on the affinity column, in
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conjunction with using porous materials for the solid support to improve binding
capacity, and longer separation channels as well as spectral multiplexing to raise the
peak capacity. Importantly, with improvements in engineering and miniaturization, a
straightforward POC instrument for multiple biomarker quantitation could result.
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5. CONCLUSIONS AND FUTURE WORK

5.1. CONCLUSIONS
5.1.1 Affinity monolith preconcentrators for microchip capillary electrophoresis
The photo-defined monolith columns presented in Chapter 2 offer several advantages
for sample preconcentration and pretreatment compared with packed columns. They
have lower backpressure compared with packed columns, are easier to fabricate and
can be integrated into polymeric microdevices. I successfully prepared these monolith
columns in microfluidic devices via photopolymerization and demonstrated the
preconcentration of amino acids on native monoliths to show the general nature of
solid phase extraction. The concentrated eluent can be readily separated by microchip
capillary electrophoresis, and threefold signal increase was achieved after extraction.
However, due to the general column selectivity and some non-specific adsorption, the
recovery of FITC-labeled amino acids on native monoliths was ~60%.

The selectivity of monolith columns can be improved by immobilizing antibodies on
them. The amount of antibodies immobilized on the 0.5-cm-long monolith column
was 250±70 mg/g (n=3) and was comparable with other methods. Moreover, unlike
direct reaction between antibody amine groups and epoxy groups on monolith
surfaces, my technique works with tenfold lower antibody concentrations (~10
µg/mL) and sixfold shorter reaction times (~4 h). In addition, coating with lysozyme
solution can effectively remove the non-specific adsorption sites on the affinity
columns. The average elution efficiency of the lysozyme-treated affinity columns was
near 90%, and the chip-to-chip variability was 3.1% (n=3). These affinity columns
can selectively enrich target analytes and reduce the signal of contaminant proteins up
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to 25,000 fold after immunoaffinity extraction. These results clearly demonstrate that
microchip affinity monoliths can selectively concentrate and purify target analytes
through specific antibody-antigen interactions.

5.1.2 Integrated microfluidic device coupling affinity extraction with microchip
capillary electrophoresis for AFP quantitation
Although the antibody-based monolith in Chapter 2 has shown promise in selective
extraction, off-chip extraction slows the total analysis speed and efficiency. It would
be beneficial to couple affinity columns with electrophoretic analysis in a single
device. With a new design, both functions can be integrated into a micromachined
system, and the monolith can be successfully prepared. However, such microdevices
only run well for simple systems such as buffered solution. Once real biological
samples such as human serum were applied, significant clogging was observed for
many devices. Therefore, in Chapter 3, I developed new affinity columns using a wall
coating protocol. To form the affinity columns, a thin film of a reactive polymer was
UV polymerized in a microchannel, and scanning electron microscopy indicated that
the channel walls were coated with ~3 µm of polymer. Antibodies were attached by
reaction between the polymer epoxy groups and antibody amine groups. Only
analytes of interest were retained on the affinity column, while non-target material
was directed into the waste reservoir. Retention and enrichment of FITC-AFP in antiAFP columns were shown through flow experiments, and negligible non-specific
adsorption of proteins was found in these affinity columns. Retained proteins were
eluted into the injection region of the capillary electrophoresis module for rapid
separation. All assays, including loading, washing, and elution steps of the affinity
extraction, as well as the capillary electrophoresis analysis, were achieved simply via
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applying voltages to reservoirs on the microdevice. By adding reservoirs containing
AFP standard into the same device, a quantitative method, either standard addition or
a calibration curve, can be performed on chip. In conjunction with laser-induced
fluorescence detection, my systems can quantify AFP at ~1 ng/mL levels in ~10 µL of
human serum in a few tens of minutes. My polymer microdevices have been applied
in determining AFP in spiked serum samples, and the results are comparable with the
values measured from a commercial ELISA kit.

5.1.3 Integrated microfluidic device for multiple biomarker quantitation in
human serum
Although the microdevices in Chapter 3 have been designed for AFP analysis, this
approach is not limited to just AFP. These microchips can be easily adapted for
detection of multiple biomarkers by simply immobilizing different antibodies in the
affinity column. However, to make a multi-biomarker system, the affinity column
properties needed be fully characterized and evaluated. In Chapter 4, I demonstrated
an integrated microfluidic system that could simultaneously quantify multiple cancer
biomarkers in human blood serum. I selected four commercially available biomarkers
(AFP, CEA, CytC, and HSP90) as test proteins. Antibodies were attached to
microchip columns, and the amounts of immobilized antibodies were characterized.
The fluorescence signals of all four proteins were in the same range after rinsing,
indicating that the derivatization reaction had little bias toward any of the four
antibodies I used. For a buffer solution containing the four target proteins and
fluorescent dye, after on-chip affinity purification, the dye peak was essentially
eliminated, while the four biomarker peaks remained. I also tested four spiked human
blood serum samples with my devices. With these samples, four proteins in the ng/mL
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range were simultaneously quantified using both calibration curves and standard
addition. In general, the calibration curve and standard addition results were close to
the known spiked concentrations. These results indicate that my integrated
microdevices can selectively retain and analyze targeted compounds in clinical
samples. Moreover, my platform is generalizable and applicable for the simultaneous
quantification of multiple biomarkers in complex samples.

5.2. FUTURE DIRECTIONS
5.2.1 Semi-permeable membrane preconcentrators
In my dissertation, I demonstrated integrated microdevices for analysis of biomarkers
in human serum. The detection limit of current devices is in the low ng/mL level for
biomarkers, which is comparable to commercial ELISA kits. A lower limit of
detection would be beneficial for trace biomarker detection. More importantly, for
each chip, the migration time of eluent to microchip CE injector needs to be fine
tuned. Too long or too short of an injection time will result in peak loss and loading
bias toward different proteins. To address these problems, I have done initial work
toward integrating a semi-permeable polyacrylamide membrane in the microchip
injector as a sample preconcentrator. This size-selective membrane, formed in situ by
focused laser polymerization, allowed small molecules like fluorescein to pass
through easily, but prevented protein transport.

Briefly, a freshly prepared acrylamide solution (total monomer concentration: 13%
and weight percentage of crosslinker: 4 %) containing 12.5% acrylamide, 0.5% N,N'methylene bisacrylamide (crosslinker), 0.1% tetramethylethylenediamine (provides
radicals for polymerization), 0.05% riboflavin (initiator of photopolymerization),1
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0.05% ammonium persulfate (provides initial radicals), and 0.1 μM fluorescein (for
visualization) in water was degassed and introduced into the microchannel via
capillary action. The monomer in the reservoirs was completely removed to reduce
siphon effects. A 488-nm laser beam was focused 10~40 μm from the double T
injection area with a 20× objective for 3 min. The unreacted monomer was flushed
out by water and Tris buffer.

The apparent pore radius (R) of my 4 % crosslinker acrylamide gel can be estimated
using the following equation where T is the total acrylamide percentage:2
R = 110 T-0.5 = 30.5 nm

(Eq. 5.1)

Even though this dimension is larger than the molecular size of most proteins, as I
summarized in Section 1.3.3, such a membrane can still enrich proteins because the
negatively charged diffuse layer on the interior of the membrane repels anions.
Consequently, protein ions should enrich at the junction of the membrane and
injection area. As a result, the injection time of eluent from the affinity column should
not change the amount of proteins injected into the separation channel.

I tested the integrated membrane preconcentration and microchip CE device with
FITC-labeled bovine serum albumin (BSA). After a 10-min enrichment, the
fluorescent signal for 100 ng/mL FITC-BSA increased ~140 fold (Figure 5.1).
However, due to some penetration of proteins into the membrane, significant tailing
was found after such a long injection time.
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Figure 5.1. FITC-BSA enrichment with an integrated semi-permeable membrane.
In addition, microchip CE of a mixture with fluorescein and FITC-labeled IgG
demonstrated selective enrichment of proteins at the injection preconcentrator (Figure
5.2). The on-chip enrichment factor for FITC-labeled IgG was ~80 fold after 4 min,
while no significant enrichment (~1.3 fold higher signal) was found for
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Figure 5.2. Selective preconcentration of FITC-IgG over fluorescein.
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Figure 5.3. Microscope image of FITC-IgG
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5.2.2 Multiplexed immunoassays based on gel particles
I have successfully demonstrated quantification of multiple biomarkers in Chapter 4.
However, such multiplexed analysis is still challenging, because of the limited
number of immobilized antibodies on the affinity column. There are two common
technologies used for multiplexing: planar arrays and suspension (particle-based)
arrays.3 Planar arrays, such as DNA and protein microarrays, are better suited for
ultra-high-density analysis,4 while suspension arrays offer ease of assay modification,
higher sample throughput, and better quality control by batch synthesis.5 To identify
each protein in the mixture, it is important to differentiate proteins. Using multiple
fluorescent signals as coding could solve this problem, but it brings higher cost with
each fluorescent dye and its own exciter and detector, with potential interference.
Therefore, a single-fluorescence method using graphical coding is more attractive.
Recently, Doyle’s group developed a simple technique to generate multifunctional
particles with distinct regions for analyte coding and target capture in microfluidic
formats.6 Briefly, two monomer streams (one loaded with a fluorescent dye for coding
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and the other with a probe) were adjacently flowed through a microfluidic channel,
and continuous-flow lithography was used to polymerize particles across the streams
(Figure 5.4). With dynamic focusing, 3-D gel particles with a sandwich shape can
also be generated.7 However, it is an on-going challenge to precisely read and decode
barcoded gel particles.8

Figure 5.4. Schematic diagram of coded gel particle synthesis (reproduced with
permission from ref. 6).

Thus, instead of using two streams of monomer, a prepolymer solution containing
glycidyl

methacrylate

(GMA,

monomer),

poly(ethylene

glycol)

diacrylate

(crosslinker, reduces non-specific adsorption of proteins), 2,2’-dimethoxy-2phenylacetophenone (photoinitiator), and 2-acrylamido-2-methylpropane sulfonic
acid (AMPS, provides negative charges)1 will be pumped through a microchannel.
Gel particles of different sizes (controlled by photomask) and charge (adjusted by
AMPS percent) can be generated easily via lithography. Different antibodies can be
anchored onto the gel particles based on the reaction between epoxy groups of GMA
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and amine groups of antibodies. Because of the surface area of gel particles, more
antibodies can be attached than with the wall coating protocol, which in turn increases
the binding capacity for multiplex assays. To detect multiple biomarkers in human
whole blood samples, the particles anchored with different antibodies can be
immersed in fluorescently labeled sample, and then rinsed to remove any unbound
material, separated via capillary electrophoresis (because of the unique mass/charge
ratio for each particle), and decoded via CCD detector (Figure 5.5). The amount of
antigen can be calculated from the fluorescence signal of the gel particles. These gel
particles can be easily cleaned, packed, shipped, and used as part of a straightforward
POC instrument for multiple biomarker quantitation.
Gel
Waste
Rinse buffer

Separation reservoir

Fluorescently labeled serum
Laser

Dichroic mirror
CCD

Figure 5.5. Schematic diagram of analysis using affinity gel particles.

In summary, in my dissertation I have developed a novel microfluidic system
integrated with antibody-based sample purification and electrophoretic separation to
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provide fast and accurate quantitation of multiple biomarkers in human serum. Further
studies on engineering and miniaturization should enable fabrication of a POC
instrument for cancer screening. Microfluidic separation was introduced over two
decades ago and continues to grow. My work pushes the frontiers of this
miniaturization technique and demonstrates strong potential for POC applications.
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